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Abbreviations  
 
aa                                               amino-acid 
ADAMTS13 a disintegrin-like and metalloprotease domain 
with thrombospondin type-1 motif, number 13 
aPTT Activated partial thromboplastine time 
ASA                                            Average surface accessible area 
Bp     Base pair 
BS     Bleeding score 
BSS     Bleeding severity score 
cAMP     Cyclic adenosine monophosphate 
cDNA                                          Complementary Deoxynucleic acid 
CK                                             Cysteine knot 
C-terminal     Carboxy-terminal 
C8                                               Cysteine 8 
Da  Dalton 
db                                               Database 
DDAVP                               Vasopressin analogue, 1-desamino-8-D-
arginine-vasopressin 
dl                                                Deciliter 
DMEM                                        Dulbecco’s Modified Eagle’s Medium 
DNA           Deoxynucleic acid 
DSS                                           Donor splice site 
EDTA           Ethylenediamintetraacetic acid 
ELISA                                        Enzyme-linked immunosorbent assay 
ER                                             Endoplasmic reticulum 
FBS     Fetal bovine serum 
FVIII                                           Factor VIII 
FVIII:C                                       Factor VIII activity 
F8     Factor VIII gene 
GPIb                                           Platelet glycoprotein Ib 
GPIIb–IIIa   Glycoprotein IIb–IIIa      
HEK 293                                      Human embryonic kidney 293 cells 
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HMW                                           High-molecular weight 
HMWM                                       High-molecular weight multimers   
Hr                                                Hour 
IP                                               Index patient 
ISTH SSC                                International Society on Thrombosis and 
Haemostasis Scientific and Standardisation 
Committee 
IU           International unit 
kb           Kilo base pair 
kDa                                            Kilo Dalton 
MD                                             Molecular dynamic 
mg                                              Miligram 
min           Minute 
ml                                               Milliliter 
MLPA                                        Multiplex ligation-dependent probe amplification 
mRNA                                       Messenger RNA 
µg                                               Microgram 
µm                                             Micrometer 
N                                              Normandy  
ns                                              Nanosecond 
nt           Nucleotide 
PBS                                            Phosphate Buffered Saline 
PCR           Polymerase chain reaction 
PDI                                            Protein disulphide isomerase 
PFA-100                                    Platelet function analyzer 100 
PolyPhen                                    Polymorphism Phenotyping 
RER                                            Rough endoplasmic reticulum 
RGD                                           Arg-Gly-Asp 
RIPA                                           Ristocetin induced platelet aggregation 
RNA                                            Ribonucleic acid 
ROG                                          Radius of gyration 
rVWF                                          Recombinant von Willebrand factor 
SDS           Sodium dodecyl sulfate 
SIFT                                           Sorting Intolerant From Tolerant 
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TGN                                           Trans-Golgi network 
TIL                                            Trypsin-inhibitor-like 
UL-VWF                                      Ultra large von Willebrand factor 
VWC -domain                             von Willebrand C-domain 
VWD                                          von Willebrand disease 
VWD-domain                             von Willebrand D-domain 
VWF                                           von Willebrand factor 
VWF                                            VWF gene 
VWF:Ag                                      von Willebrand factor antigen 
VWF:CB                                     von Willebrand factor: collagen binding 
VWF:FVIIIB                                 VWF: FVIII binding 
VWF:GPIbB                               von Willebrand factor: GPIb binding 
VWF:RCo                                   von Willebrand factor: ristocetin cofactor 
WPB                                         Weibel-Palade body 
WT           Wild type 
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Summary 
 
Von Willebrand disease (VWD) is the most common inherited bleeding disorder. 
It is caused by quantitative or qualitative defects of the von Willebrand factor 
(VWF) which has crucial roles in hemostasis. VWD is classified into three 
primary categories. Types 1 and 3 represent partial and total quantitative 
deficiency of VWF, respectively. Type 2 is due to qualitative defects of VWF, 
and is divided into four secondary categories 2A, 2B, 2M and 2N. In this study 
we explored genotype and phenotype characteristics of a cohort of VWD 
patients with the aim of dissecting the distribution of mutations in different types 
of VWD. Mutation analysis of 114 patients diagnosed to have VWD was 
performed by direct sequencing of the VWF gene (VWF). Large deletions were 
investigated by multiplex ligation-dependent probe amplification (MLPA) 
analysis. The results showed a mutation detection rate of 68%, 94% and 94% 
for VWD type 1, 2 and 3, respectively. In total, 68 different putative mutations 
were detected. Twenty six of these mutations were novel. In type 1 and type 2 
VWD, the majority of identified mutations (74% vs 88.1%) were missense 
substitutions while mutations in type 3 VWD mostly caused null alleles (82%). In 
addition, the impact of five detected novel cysteine missense mutations residing 
in D4-CK domains was characterized on conformation and biosynthesis of 
VWF. Transient expression of human cell lines with wild-type or five mutant 
VWF constructs was done. Quantitative and qualitative assessment of mutated 
recombinant VWF was performed. Storage of VWF in pseudo-Weible-Palade 
bodies (WPBs) was studied with confocal microscopy. Moreovere, structural 
impact of the mutations was analyzed by homology modeling. Homozygous 
expressions showed that these mutations caused defects in multimerization, 
elongation of pseudo-WPBs and consequently secretion of VWF. Co-
expressions of wild-type VWF and 3 of the mutants demonstrated defect in 
multimer assembly, suggesting a new pathologic mechanism for dominant type 
2A VWD due to mutations in D4 and B domains. Structural analysis revealed 
that mutations either disrupt intra-domain disulfide bonds or might affect an 
inter-domain disulfide bond.  
Summary 
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In conclusion, our study extends the mutational spectrum of VWF, and improves 
the knowledge of the genetic basis of different types of VWD. The gene 
expression studies highlight the importance of cysteine residues within the C-
terminal of VWF on the structural conformation of the protein and consequently 
multimerization, storage, and secretion of VWF. 
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1.1 VWF  
 
Von Willebrand factor (VWF) is a large multimeric plasma glycoprotein that first 
was identified by Zimmermann in 1971.1, 2 The VWF plays a crucial role in 
hemostasis. It mediates platelet adhesion in primary hemostasis. In addition, 
VWF carries factor VIII (FVIII) in the circulation, protecting it from rapid 
proteolytic degradation and delivering it to sites of vascular damage for 
secondary hemostasis.1, 3 Normal circulating VWF is composed of a series of 
heterogeneous multimers ranging in size from about 500 kDa to over 20000 
kDa.4 The mean plasma level of VWF is 100 IU dL-1 but the population 
distribution is between 50 IU dL-1 and 200 IU dL-1.5 Many factors such as ABO 
blood group, gender, age, hormonal regulation, and inflammatory states have 
been described to have an impact on VWF levels.6  
Deficient or defective VWF results in von Willebrand disease (VWD), a common 
inherited bleeding disorder.7  
 
1.1.1  VWF gene 
 
The VWF gene (VWF) is located on the short arm of chromosome 12 (12p 
13.2). It spans approximately 178 kb of genomic DNA, and is transcribed into an 
8.8 kb mRNA. The VWF gene comprises 52 exons, most exons are ranging 
from 40-342 bp, but exon 28 is exceptionally larger (1.4 kb in size).1, 8 A non-
coding partial VWF pseudogene has been identified on chromosome 22 
(22q11.22 to 22q11.23). The pseudogene is 97% similar in sequence to the 
coding gene, corresponding to exons 23 to 34 of VWF. Gene conversion events 
between VWF and VWF pseudogene have been demonstrated.9, 10 VWF is 
highly polymorphic with about 200 reported polymorphic variations in VWF 
recorded in the International Society on Thrombosis and Haemostasis Scientific 
and Standardisation Committee on VWD database (ISTH SSC-VWD db 
http://vwf.group.shef.ac.uk/index.html accessed January 2013). This highly 
polymorphic nature of VWF, along with its large size and the presence of a 
partial pseudogene make genetic analysis of VWF challenging.10, 11 
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1.1.2  VWF protein structure and domain organization 
 
The VWF monomer is comprised of 2813 amino acids (aa). The VWF protein is 
remarkably rich in cysteines, which comprise 234 of the 2813 (8,3%) residues in 
prepro VWF.3, 12 The VWF protein is extensively glycosylated, oligosaccharide 
side chains make up approximately 20% of the mass of VWF, and are believed 
to affect its structural and functional integrity .13 
The prepro VWF precursor is composed of five types of domains that are 
constructed as repeats in the following order: D1-D2-D’-D3-A1-A2-A3-D4-B1-
B2-B3-C1-C2-CK (Figure 1.1 A).14 The D1 and D2 domains comprise the 
propeptide and are cleaved during proteolytic processing to generate the 
mature VWF. The remaining domains in the mature VWF carry out specific 
functions. 2, 15 
The domains may be characterized as structural or functional, depending on 
their role in VWF structure or its interaction with other factors. Structural 
domains are involved in the post-translational processing of VWF, for example 
the cysteine knot (CK) domain is required for dimerization of VWF monomers 
and the D1, D2 and D3 domains for proper multimerization of VWF dimers.16 All 
‘D’ domains (except D4) contain a CGLC consensus sequence that is highly 
homologous to the active site of proteins harbouring protein disulphide 
isomerase (PDI) activity.16, 17, 18 PDI is the enzyme that catalyses thiol-
disulphide interchange reactions in protein substrates, leading to disulphide 
formation and folding of the protein.17 In this respect, ability of the D1, D2 and 
D3 domains to promote interchain disulphide bonding and multimerization can 
be ascribed to the intrinsic PDI activity of these domains.17, 18  
Functional domains include those that contain cleavage sites for proteolysis 
(domain A2) and binding sites for collagen (domains A1 and A3), platelets 
(domain A1 for platelet glycoprotein Ib (GPIb) receptors), and FVIII (domains D3 
and D’) (Figure 1.1A).16, 18 Moreover, the C1 domain contains the RGD 
sequence (Arg-Gly-Asp) recognized by platelet integrin GPIIb/IIIa receptors. 
Another RGD sequence is present in the propeptide, but no role in integrin 
binding has been observed. 3, 17 The carboxy-terminal domains, namely D4-B1-
3-C1-2, are cysteine-rich, which may suggest structural importance.16  
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Recently, Zhou et al. have re-evaluated the VWF domain structure, using the 
updated information on the structure of these homologous domains in 
combination with electron microscopy techniques.14, 19 The previous B and C 
regions of VWF are re-annotated as 6 tandem von Willebrand C (VWC) and 
VWC-like domains.19 Moreover, the VWF D domains are annotated as 
containing von Willebrand D (VWD-domain), cysteine 8 (C8), trypsin-inhibitor-
like (TIL), E or fibronectin type 1-like domains and a unique D4N sequence in 
D4 (Figure 1.1B). However, the original domain designations still predominate in 
the VWF literature. 
 
 
 
 
Figure 1.1. Structural and functional domains of von Willebrand factor (VWF).  
Part A illustrates the original domain assignment of VWF along with binding and 
cleavage sites, as well as dimerization and multimerization regions. Exons encoding 
each domain are shown (adapted from Goodeve AC)1. Part B illustrates the updated 
domain annotation of VWF (adapted from Zhou YF et al.)19. 
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1.1.3  VWF biosynthesis 
 
VWF is produced exclusively by endothelial cells present in different tissues and 
by the platelet precursor, megakaryocytes.2, 17 Platelet VWF is stored within 
cells and has not been shown to contribute significantly to plasma VWF.13 
The VWF primary translation product is a 2813-aa pre-pro-polypeptide (350 
kDa) which encompasses a 22-aa classic signal sequence, a 741-aa propeptide 
and a 2050-aa mature VWF protein.17, 20 Posttranslational processing of VWF 
includes dimerization, glycosylation, sulfation, propeptide cleavage, and 
multimerization, followed by storage or secretion (Figure 1.2).3  
 
Dimerization and multimer assembly 
 
After the cleavage of the signal peptide and translocation into the endoplasmic 
reticulum (ER), pro-VWF subunits dimerize in a ‘tail-to tail’ manner through 
disulfide bonds that form between the C-terminal residues (Figure 1.2).2, 3 The 
dimerization function requires only sequences within the last 150 residues. The 
cysteins within the last 150 aa residues of the VWF subunit form intersubunit or 
intrasubunit disulfide bonds. The carboxyl-terminal 90 residues comprise the 
“CK” domain that is homologous to the “Cysteine knot” superfamily of proteins. 
The family members share a tendency to dimerize, often through disulfide 
bonds.15, 21 
The pro-VWF dimers are subsequently transported to the Golgi complex, where 
multimerization and the proteolytic removal of the large VWF peptide take place 
(Figure 1.2).2 In the Golgi apparatus and post-Golgi compartments, dimers 
undergo multimerization to form tetramers, hexamers and so on, generating 
high-molecular weight (HMW) multimers containing up to 100 monomers that 
may exceed 20 million Da in size.18 Multimerization occurs through additional 
head-to-head disulfide bonds near the amino-termini of the subunits.3 The VWF 
multimer assembly appears to involve an unique oxidoreductase mechanism 
that is activated by the low pH of the Golgi apparatus.15 The key to multimer 
assembly is the N-terminal D1-D2-D’-D3 region of proVWF. The reaction 
appears to proceed through a transient, disulfide-linked intermediate between 
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the propeptide and the D3 region of VWF that forms in the ER and resolves in 
the Golgi to yield disulfide-linked VWF multimers.22  
The polymerization process is accompanied by proteolytic cleavage (probably 
by furin) of the propeptide in the trans-Golgi network, yielding mature VWF 
multimers and propeptide dimers. The propeptide cleavage occurs after the 
argenine residue at position 763. After cleavage, VWF and the VWF propeptide 
remain non-covalently associated within the cell.15, 17 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Biosynthesis of VWF (adapted from Millar CM et al.).13 
After the cleavage of the signal peptide and translocation into the rough endoplasmic 
reticulum (RER), initial glycosylation and dimerization of pro-VWF takes place. The 
pro-VWF dimers are subsequently transported to the Golgi complex, where they 
undergo post-translational glycosylation, sulphation and multimerization. Finally, the 
propeptide is cleaved in the trans-Golgi network (TGN) and fully functional VWF 
multimers are stored in Weibel-Palade bodies (WPB). 
 
Chapter 1. General introduction and outline 
 
 
 - 7 - 
Glycosylation, sulfation 
 
The mature subunit is extensively glycosylated with 12 N-linked and 10 O-linked 
oligosaccharides, and the propeptide has three more potential N-glycosylation 
sites.12 The N-linked carbohydrates are added in high-mannose form in the ER 
and are further processed to complex forms in the Golgi apparatus. O-
glycosylation and sulfation of some N-linked oligosaccharides also occur in 
Golgi compartments.23, 24 The N-linked oligosaccharides of VWF are unusual 
compared to those of other plasma glycoproteins because they contain ABO 
blood group oligisacharides.12 The antigens of the ABO blood group system (A, 
B, and H determinants, respectively) consist of complex carbohydrate 
molecules. It is demonstrated that ABH structures are carried on the N-linked 
oligosaccharide chains of VWF according to the blood type of the individual.23, 25  
 
Intracellular storage 
 
VWF produced by endothelial cells is either secreted constitutively or stored in 
Weibel-Palade bodies (WPBs), while VWF produced by megakaryocytes that 
are later converted into platelets, is stored in α-granules.12  
WPBs are rod-shaped, membrane enclosed organelles, approximately 0.2 µm 
wide and up to 5 µm long.15, 17 They consist of densely packed tubular arrays of 
VWF which are composed of VWF multimers and propeptide. Tubulation allows 
a 100-fold compaction of VWF, without which intracellular storage of VWF 
would be impossible. In addition, the tubular storage of VWF multimers is critical 
for the orderly secretion of long VWF strings without tangling.12, 26  
WPBs initially form at the TGN and subsequently undergo maturation, before 
accumulating within the cytoplasm of endothelial cells. The VWF multimers and 
propeptide condense into tubules and are incorporated into nascent vesicles 
that protrude from the TGN. After budding from the TGN, immature WPBs 
remain in a perinuclear location, where they acquire additional membrane 
proteins and then disperse throughout the cytoplasm.20, 27 
The VWF is a prerequisite for the existence of WPBs.28 It has been proposed 
that the targeting of VWF to the WPBs occurs as a consequence of selective 
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aggregation, by means of multimerization of this protein in the trans-Golgi 
network.27, 29 The N-terminal D1-D2-D’-D3 domains and the acidic pH of the 
trans-Golgi are required to target and package VWF into WPBs. Thus, multimer 
assembly and tubular packing both depend on the propeptide, D’D3 domains 
and acidic pH.15, 30 
Recently, it has been demonstrated that the VWF C-terminals zip up and form a 
structure resembling a bouquet of flowers, where the A2, A3, and D4 domains 
comprise the flower part and the six VWC domains configure the stem. Dimeric 
bouquets are essential for correct VWF dimer incorporation into growing tubules 
and to prevent crosslinking between neighbouring tubules.31, 32 Moreover, it was 
found that the last steps in VWF biosynthesis, interdimer N-terminal disulphide 
bond formation and cleavage by furin, appear to occur during or after assembly 
of individual VWF dimers onto the growing ends of tubules in nascent WPBs.31 
Helical assembly thus provides a template for disulphide bond formation during 
N-terminal concatamerization.31 The lack of crosslinking between tubules 
promotes orderly unfurling of VWF from the ends of helices similarly to orderly 
uncoiling of a rope.26 Dimeric bouquets are undoubtedly also important in 
compaction of WPBs during maturation and their expansion during secretion.31  
Megakaryocytes synthesize large VWF multimers and package them into 
platelet α-granules that are spherical rather than cigar-shaped. The VWF 
multimers in α-granules are organized into clusters of tubules with dimensions 
similar to those of VWF tubules in Weibel–Palade bodies.27, 30  
 
VWF secretion and catabolism 
 
Secretion of stored VWF from endothelial cells occurs through both a 
constitutive and a regulated pathway.2 The majority of endothelial-derived VWF 
is secreted via the constitutive pathway, which contributes to approximately 
95% of plasma VWF; the remaining VWF is stored within WPBs of endothelial 
cells, and secreted via the regulated pathway on stimulation by 
secretagogues.13 Megakaryocytes, however, lack the regulatory pathway, VWF 
is constitutively secreted and has not been shown to contribute significantly to 
plasma VWF.2, 13 
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It would be of great interest to define in detail the molecular mechanisms and 
machinery that underlie VWF secretion in health and disease.33 In response to 
pathological stimuli, such as vascular injury and inflammation, the circulatory 
concentration of VWF increases rapidly mediated by secretagogues. The 
secretagogues can be divided into two distinct groups: Ca2+-raising agonists 
(thrombin and histamine) and cAMP-raising agonists (epinephrine and 
vasopressin).28, 33 In vivo, plasma VWF and FVIII levels rise rapidly after 
administration of the vasopressin analogue, 1-desamino-8-D-arginine-
vasopressin (DDAVP), mediated by an increase in cAMP. The ability of DDAVP 
to raise plasma VWF and FVIII levels has made it a major drug for the treatment 
of VWD and hemophilia A.3, 12  
Upon activation of endothelial cells by agonists, the WPBs fuse with the plasma 
membrane and release their contents into the blood circulation.20, 33 During 
normal exocytosis, the shift in pH from pH 5.5 within the WPBs to the neutral pH 
of plasma leads to the unfolding of compact VWF tubules to VWF strings 100 
times longer than the WPBs.15, 26  
The length of the released VWF strings is typically several 100µm long but can 
reach extraordinary lengths of up to 1mm. These long VWF strings could arise 
through end-to-end self-association of VWF multimers.34 Presumably, the 
unpaired cysteine thiols localized to the N-terminal D3 and C-terminal C 
domains are involved in VWF self association.14, 35 Moreover, high shear stress 
changes the shape of the molecule from a globular form to an elongated or 
stretched form that is crucial for the interaction with platelets.18  
The molecular size of VWF is critical for its physiologic function as a mediator of 
platelet adhesion and aggregation in primary hemostasis. The high-molecular-
weight-multimers (HMWMs) are biologically most active and are essential to 
maintain hemostasis under conditions of high shear stress in the 
microvasculature.36 However, the ultra large VWF (UL-VWF) is potentially 
harmful in the normal circulation and must be processed into smaller, less 
reactive molecules that will not precipitate unwanted platelet aggregation.34 The 
highly pro-thrombotic UL-VWF is cleaved by the specific VWF cleaving protease 
ADAMTS13 (a disintegrin-like and metalloprotease domain with 
thrombospondin type-1 motif, number 13).36  The ADAMTS13 cleavage site in 
Chapter 1. General introduction and outline 
 
 
 - 10 - 
VWF (Met1605-Tyr1606) is normally hidden within the middle of the folded A2 
domain.34 High shear stresses can unfold the ADAMTS13 cleavage site in the 
A2 domain.2  
The half-life of the circulating VWF multimers is ~ 12h.12 It is demonstrated that 
macrophages and FVIII, mainly in the liver, mediate the removal of VWF from 
circulating blood. However, the precise cellular membrane receptors for VWF 
remain unknown.2  
  
1.1.4 VWF functions 
 
The VWF protein has three main recognized hemostatic functions, which are to 
mediate interactions of platelets to subendothelial matrix and platelets to 
platelets (platelet adhesion and platelet aggregation), and to serve as a carrier 
of factor VIII in the circulation system.2 Recent studies have stated that VWF 
may have other, non hemostatic functions in angiogenesis, cell proliferation, 
inflammation, and tumor cell survival.2, 14, 37 
 
Interactions between VWF and the subendothelial matrix 
 
VWF performs a bridging function by binding the platelets to the extracellular 
matrix at sites of vascular injury.3 When vessel wall subendothelium is exposed, 
VWF binds to collagen in the subendothelial matrix. The high shear stress 
allows conformational changes within VWF, which can result in the exposure of 
binding sites for platelets or collagen.2, 34 The A1 domain of VWF interacts 
mainly with collagen type VI but can also bind, with less affinity, to collagen 
types I and III. The A3 domain can also bind to collagens, namely collagen 
types I and III.2  
 
Role of VWF in platelet adhesion and aggregation 
 
Under physiological conditions, circulating platelets are recruited from the blood 
flow to injury sites, where they act to prevent excessive bleeding. The highly 
polymerized VWF molecules are required to achieve efficient platelet adhesion 
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and aggregation.17 The plasma VWF adheres to circulating platelets through 
two membrane receptors: glycoprotein Ib (GPIb) and the glycoprotein IIb–IIIa 
(GPIIb–IIIa) complex.2,3 Upon exposure of vessel subendothelial matrix, VWF 
undergoes a conformational change after matrix binding and subsequently the 
binding site for the platelet receptor GPIb, located in the A1 domain of VWF, 
becomes accessible. 
The platelet GPIIb/IIIa receptor only becomes available for VWF binding after 
platelet activation. Platelets are activated at sites of vascular injury by a variety 
of agonists. In addition, binding of VWF to the platelet GPIb receptor appears to 
activate platelets, making the GpIIb/IIIa receptor available for ligand binding. 
The RGD sequence near the C-terminus of VWF seems to be responsible for 
VWF binding to GpIIb/IIIa.3  
GPIb participates mainly in platelet-vessel wall adhesion, while the GPIIb–IIIa 
complex is involved in both platelet-vessel wall adhesion and crosstalk between 
platelets. VWF is the only ligand that promotes platelet adhesion by attaching to 
both of these receptors.2 Addition of a second layer of platelets (aggregation) 
involves binding of VWF to the GPIb and GPIIb/IIIa platelet receptors and of 
fibrin to GPIIb/IIIa. This results in forming a layer of VWF and fibrin coating the 
adhered platelets which functions as a platform for recruiting more circulating 
platelets. The aggregation of platelets continues until the injury is sealed off and 
a stable platelet plug has been formed.38 
 
Carrier of factor VIII 
 
VWF forms a complex with FVIII in plasma through a non-covalent interaction.3 
FVIII is a cofactor of the intrinsic clotting cascade, and its deficiency manifests 
as hemophilia A. VWF protects FVIII from degradation and may also serve to 
localize FVIII to the site of the clot. This phenomenon may be mediated by one 
or a combination of the following mechanisms: (1) structural stabilization of 
FVIII; (2) inhibition of phospholipid-binding proteins that target FVIII for 
proteolytic degradation; (3) inhibition of FVIII binding to activated FIX to 
stimulate the coagulation pathway, and (4) prevention of FVIII cellular uptake 
via scavenger cell receptors.2  
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FVIII binds to VWF within the N terminal of D’ and D3 domains of VWF 
corresponding to residues 763-1035.39 
 
 
1.2 VWD 
 
Von Willebrand disease (VWD) is the most common inherited bleeding disorder. 
VWD has a prevalence of about 1% in the general population, but only 
approximately 1 in 10,000 individuals has clinically significant bleedings.1, 40 
VWD was first described in 1926 by Erik von Willebrand in a Finnish medical 
journal.40 He described a young woman who bled to death at the time of her 
fourth menstrual period. Since then, significant advances in clinical and 
laboratory phenotypic description of patients and understanding of genetics of 
VWD has increased our knowledge on this disorder and its pathophysiology.16, 
40
 However, the molecular basis of VWD remains the subject of ongoing 
investigations.7 
VWD is caused by quantitative and/or functional deficits of VWF.16 
Characteristic bleeding symptoms include frequent nose bleeding, easy 
bruising, oral cavity bleeding, menorrhagia, bleeding after dental extraction, 
surgery, and childbirth.7 Patients with severe forms of VWD may also suffer 
from joint, muscle and central nervous system bleeding.16  
VWD has been classified into three primary categories. Types 1 and 3 VWD 
represent quantitative variants; type 1 VWD is a partial quantitative deficiency 
and type 3 VWD is a virtually complete quantitative deficiency of VWF. Type 2 
VWD is characterized by a qualitative deficiency and defective VWF and is 
further classified into the four types 2A, 2B, 2M, and 2N.7, 18 The functional 
defects lead to enhanced (2B) or reduced (2A, 2M) platelet interaction or 
impaired binding to FVIII (2N).1 Generally, type 1, type 2A, type 2M and type 2B 
VWD are inherited in an autosomal dominant pattern, while type 3 and type 2N 
VWD are inherited in an autosomal recessive pattern. 
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1.2.1  Diagnosis and classification 
 
The diagnosis and classification of VWD requires a combination of patients’ 
medical history, specialized laboratory tests which can determine quantitative or 
qualitative defects in VWF and genetic testing.18, 41 The correct classification of 
VWD facilitates the treatment and counseling of patients with VWD. In practice, 
distinctions between certain VWD types are not always easy to make.42 
 
Bleeding history 
 
A standardized bleeding history of the patient is a prerequisite for proper 
diagnosis of a patient with presumed VWD. This may be carried out by a 
standard questionnaire.43 In addition, the utility of standard clinical assessment 
tools like bleeding severity score (BSS) to quantify bleeding symptoms 
facilitates diagnosis.7 The BSS is a summary score from -3 to 45, based on the 
presence of various types of bleedings.41  
 
Laboratory testing 
 
For patients suspected of having a bleeding disorder, a number of laboratory 
tests may be necessary for proper diagnosis. Initial standard tests include 
activated partial thromboplastin time (aPTT), FVIII activity (FVIII:C), bleeding 
time and platelet function analyzer 100 (PFA100) assay. The specific assays 
important for VWD diagnosis are VWF antigen (VWF:Ag) determination, 
VWF:Ristocetin Cofactor activity (VWF:RCo), VWF:collagen binding (VWF:CB) 
and VWF:GPIb binding (VWF:GPIb).18, 44 If abnormal results are obtained, 
specific assays should be performed to determine the subtype of VWD, such as 
multimer analysis, RIPA (Ristocetin induced platelet aggregation), VWF:FVIIIB 
(binding of FVIII to VWF) assay, and if indicated, molecular testing.6, 7, 18 
VWF antigen (VWF:Ag): Quantity of VWF protein (antigen) in the plasma, 
measured antigenically using enzyme-linked immunosorbent assay (ELISA) or 
latex immunoassay. The normal range that should be determined independently 
by each laboratory is approximately 50–200 IU/dL.7 
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Ristocetin cofactor activity assay (VWF:RCo): This assay determines the 
ability of plasma VWF to interact with platelet GPIb, initiated by the antibiotic 
ristocetin. The normal range is approximately 50–200 IU/dL.7 
Collagen binding assay (VWF:CB): This test determines the ability of VWF to 
bind to collagen (a subendothelial matrix component). The normal range is 
approximately 50–200 IU/dL.7 
FVIII activity (FVIII:C): Functional FVIII assay that determines the activity of 
FVIII in the coagulation cascade. The normal range is approximately 50–150 
IU/dL.7 
VWF multimer analysis: SDS-agarose gel electrophoresis is used to 
determine the distribution of VWF oligomers in the plasma. High-resolution 
agarose-gel electrophoresis demonstrated that circulating VWF has a complex 
multimeric structure (Figure 1.3). The multimeric pattern of VWF that is seen on 
SDS/agarose-gel electrophoresis consists of regularly spaced bands while each 
band exhibits a triplet structure appearance. The smallest detectable subunit is 
a dimer with a molecular mass of ~540 kDa. The largest molecules exceed 
10,000 kDa. The triplet bands of VWF are composed of mature, central band, 
and cleaved subunits by ADAMTS13 represented by a faster migrating satellite 
band and a slower migrating satellite band (Figure 1.3).5, 45, 46 
Ristocetin induced platelet aggregation (RIPA): The RIPA test evaluates the 
ristocetin-induced aggregation of platelet-rich plasma. It is used to identify 
patients with type 2B and discriminates patients with type 2 VWD from those 
with type 1 VWD.43 
Binding of FVIII to VWF (VWF:FVIIIB): This test that determines the ability of 
VWF to bind FVIII is useful for the identification and differential diagnosis of type 
2N VWD. 
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Molecular genetic analysis 
 
Molecular genetic analysis of patients is useful to further categorize VWD, and 
numerous mutations in the gene encoding VWF have been identified that 
correlate with specific subtypes of VWD.18  
 
Classification 
 
The International Society on Thrombosis and Haemostasis Scientific and 
Standardisation Committee (ISTH-SSC) on VWF provide recommendations for 
classification of VWD patients in 1994, and updated in 2006. 42 Table 1.1 
summarizes the classification of VWD based on ISTH-SSC VWF guidelines. 
 
 
 
Figure 1.3. VWF multimer patterns in normal plasma and different variants of 
type 2 VWD. VWF multimers were separated by SDS gel electrophoresis and 
visualized by immunostaining. The triplet structures include central band and 2 
flanking subbands. The image is adapted from the ISTH SSC VWD homepage. 
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1.2.2  Characterization of VWD subtypes 
 
VWD type 1 
 
Type 1 VWD is the most common form of the disorder and accounts for up to 
70% of all VWD. A VWF level less than 30–40 IU/dL indicates type 1 VWD.18 
However, it can be difficult to diagnose due to factors influencing VWF levels in 
plasma including environmental and genetics factors.47 One of the major 
determinants of plasma VWF:Ag levels is the ABO blood group of an 
individual.13, 48 ABO blood group O has been known to be more prevalent in 
type 1 VWD than in the normal population and is associated with VWF levels 
approximately 25% lower than the population average. The effect of blood-
VWD 
Type 
Description 
 
1 
 
 
Partial quantitative deficiency of VWF 
Reduction of VWF:Ag, VWF:Ag/VWF:RCo>0.6, normal VWF multimer 
structure 
 
2 
 
Qualitative defects of VWF 
 
2A 
 
Decreased VWF-dependent platelet adhesion 
Associated with deficiency of HMW-multimers, VWF:Ag/VWF:Rco<0.6. 
 
2M 
 
 
Decreased VWF-dependent platelet adhesion. 
VWF:Ag/VWF:Rco<0.6 and/or reduced VWF:CB, and normal VWF 
multimer pattern 
 
2B 
 
 
Increased affinity for platelet GPIb; 
Characterized by increased RIPA at low ristocetin concentrations, 
and deficiency of HMW-multimers 
 
2N Markedly decreased binding affinity for FVIII (reduction in VWF:FVIIIB). 
 
3 
 
Virtually complete deficiency of VWF  
VWF:Ag <5 IU/dL and FVIII:C<10 IU/dL. 
 
Table 1.1. Classification of VWD (adapted from Sadler JE, et al.)42 
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group O appears to be due to increased VWF clearance from plasma; A and B 
blood-group glycosylation protects VWF from clearance,.1, 49, 50 
The potential pathogenetic mechanisms characterized in type1 VWD to date 
include impaired biosynthesis, clearance (decreased survival) and intracellular 
retention of VWF.51  
 
VWD Type 2 
 
Type 2 VWD accounts for approximately 25% of all VWD.7 Type 2 VWD is 
characterized by qualitative VWF deficiency. Levels of VWF:Ag may be 
decreased, normal or even elevated, but structural or functional defects lead to 
impaired activity.16 Many type 2 VWD phenotypes can be distinguished from 
VWD type 1 by their decreased ratios of functional parameters, i.e. VWF:RCo, 
VWF:CB, VWF:GPIbB, VWF:FVIIIB, respectively, to VWF:Ag.  Type 2 VWD 
subtypes include types 2A, 2B, 2M and 2N.51 However, reliable classification of 
patients with VWD types 2A, 2B and 2M additionally requires multimer 
analysis.16 
 
Type 2A VWD is the most common form of type 2 VWD which is associated 
with reduced platelet binding due to significant reduction or absence of VWF 
HMWM.16 The hallmark of type 2A disease is a low VWF:RCo to VWF:Ag ratio 
(< 0.6) and impaired RIPA.52 Four different subtypes of VWD type 2A including 
IIA, IIC, IID, IIE can be distinguished by multimer analysis indicating different 
underlying mechanisms (Figure 1.3).1, 16 Type 2A (IIA) VWD results from 
mutations located in the A1 and A2 domains, which cause intracellular retention 
of HMWM (Group I) or enhanced susceptibility to ADAMTS13 cleavage (Group 
II). Type 2A VWD can also be caused by mutations interfering with 
multimerization assembly which either located in multimerization region (IIC and 
IIE) or in dimerization region (IID).53, 54 
 
In type 2M VWD, platelet adhesion is defective despite a normal multimeric 
structure of VWF.  The reduced capability for platelet adhesion is reflected by a 
low level of VWF:RCo or/and VWF:CB.53, 55 Type 2M VWD typically results from 
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mutations disrupting binding of VWF to platelets (in A1 domain) or impairing 
collagen binding (mostly in A3 domain).53   
Type 2B VWD is due to a gain-of-function mutation associated with increased 
affinity for platelet GPIb.52 Although patients with type 2B VWD show loss of 
HMWM like type 2A VWD patients (Figure 1.3), they can be diagnosed 
phenotypically by enhanced RIPA at low concentration of ristocetin. In patients 
with classic type 2B, development of thrombocytopenia may occure during 
stressful situations, such as severe infection, surgery or pregnancy.1 Type 2B is 
the result of missense substitutions in the GPIb binding region of VWF, the A1 
domain.  
Type 2N VWD (‘N’ for Normandy) represents forms of the disease with 
defective VWF:FVIII binding,thereby mimicking haemophilia A.16 Symptoms 
largely result from reduced FVIII levels. VWF:RCo and VWF:Ag levels can be 
within the normal range, while FVIII:C is typically 5–40 IU/dL. 
 
VWD Type 3  
 
Type 3 VWD is the most severe and infrequent form of the disease,55 and 
accounts for <5% of VWD patients.7 Type 3 VWD is identified by VWF:Ag 
levels< 1% and moderate deficiency of FVIII (levels <10%).  
It is an autosomal-recessive form of the disease due to homozygosity or 
compound heterozygosity of two mutations resulting in lack of VWF expression. 
In most cases, heterozygous mutation carriers of VWD type 3 are unaffected.16 
Phenotypic analysis is generally sufficient for diagnosis of the disorder, although 
molecular analysis can be useful where carrier status determination or prenatal 
diagnosis is required. 
 
1.2.3 Treatment 
 
The most important treatment options available for patients with VWD include 
stimulating the release of VWF from endogenous storage organelles by 
DDAVP, or replacement with plasma-derived VWF/FVIII concentrates.16, 53, 56 
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Other treatments that can reduce symptoms include fibrinolytic inhibitors and 
hormones for menorrhagia.7 
DDAVP induces a prompt two- to fourfold increase in VWF plasma 
concentration and has therefore a significant role in the prevention and 
treatment of bleeding episodes in patients with VWD. The effectiveness of 
DDAVP is very variable between patients and dependent on the type of genetic 
defect in VWF.28 Stimulation of endogenous VWF with DDAVP usually works 
well in patients with type 1 VWD.53 Response to DDAVP among patients with 
type 2 VWD is heterogenous. In general, most type 2 patients produce 
dysfunctional VWF, so increasing levels of dysfunctional endogenous VWF with 
DDAVP might not be a viable strategy. Specifically, patients with type 2B VWD 
are usually not treated with DDAVP due to the occurrence of severe 
thrombocytopenia.16 DDAVP is not effective in patients with type 3 VWD 
because these patients cannot produce any VWF. Type 3 VWD patients must 
be treated with VWF-containing concentrates.57 
Therefore, the determination of correct subtype of VWD is important for 
selecting the available treatment options. 
 
 
1.3 Aim and outline of the thesis 
 
Diagnosis and classification of VWD can be complex because of variability in 
clinical manifestation and considerable heterogeneity in its molecular basis. 
Increasing our knowledge of the molecular biology and etiology of VWD will 
allow improvements in diagnosis, classification and consequently treatment of 
VWD patients. The main aim of the study was expanding our understanding of 
the molecular basis of different types of VWD to establish phenotype-genotype 
correlations. In addition, we aimed to elucidate the pathophysiological 
mechanisms of novel cysteine missense mutations within C-terminal domains of 
VWF which cause quantitative or qualitative VWD. 
In chapter 2, we explored genotype and phenotype characteristics of a cohort 
of patients with VWD with the aim of dissecting the distribution of mutations in 
different types of VWD and correlate them to the clinical disease severity. 
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Moreover, the pathogenicity of novel candidate missense mutations and 
potential splice site mutations was predicted by in silico assessments. 
In chapter 3, the presence of large deletions in VWF was investigated by 
multiple ligation-dependent probe amplification (MLPA), a gene dosage-based 
analysis method. The large deletions are likely to be missed by direct 
sequencing of VWF gene, where a heterozygous deletion is masked by the 
presence of an intact second allele. The MLPA analysis was performed for 
patients in whom no causative mutation was found, or homozygous causative 
gene alterations together with homozygous known polymorphisms were 
identified.   
In chapter 4, the impact of five novel cysteine missense mutations residing in 
D4-CK domains on conformation and biosynthesis of VWF was characterized. 
These variants were identified as heterozygous in type 1 (p.Cys2619Tyr and 
p.Cys2676Phe), type 2A (p.Cys2085Tyr and p.Cys2327Trp) and as compound 
heterozygous in type 3 (p.Cys2283Arg) VWD. The effects of mutations on the 
processing of VWF including multimer assembly, its storage in Weibel-Palade 
bodies and secretion have been studied by transient expression in mammalian 
cell lines. Possible structural impact of these cysteine mutations was 
additionally studied by homology modeling. 
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Chapter 2 
 
Mutation distribution in the von Willebrand factor 
gene related to the different von Willebrand 
disease (VWD) types in a cohort of VWD patients 
 
 
Adapted from  
Yadegari H., Driesen J., Pavlova A., Biswas A., Hertfelder H.-J., Oldenburg J. 
Thrombosis and Haemostasis. 2012;108: 108(4):662-671 
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2.1 Abstract 
 
In this study we explored genotype and phenotype characteristics of patients 
with VWD with the aim of dissecting the distribution of mutations in different 
types of VWD. One hundred fourteen patients belonging to 78 families 
diagnosed to have VWD were studied. Mutation analysis was performed by 
direct sequencing of the VWF. Large deletions were investigated by MLPA 
analysis. The impact of novel candidate missense mutations and potential 
splice site mutations was predicted by in silico assessments. We identified 
mutations in 66 index patients (IPs) (84.6%). Mutation detection rate was 68%, 
94% and 94% for VWD type 1, 2 and 3, respectively. In total, 68 different 
putative mutations were detected comprising 37 missense mutations (54.4%), 
10 small deletions (14.7%), 2 small insertions (2.9%), 7 nonsense mutations 
(10.3%), 5 splice-site mutations (7.4%), 6 large deletions (8.8%) and 1 silent 
mutation (1.5%). Twenty six of these mutations were novel. Furthermore, in 
type 1 and type 2 VWD, the majority of identified mutations (74% vs 88.1%) 
were missense substitutions while mutations in type 3 VWD mostly caused null 
alleles (82%). Genotyping in VWD is a helpful tool to further elucidate the 
pathogenesis of VWD and to establish the relationship between genotype and 
phenotype.  
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2.2 Introduction 
 
Correct diagnosis and classification of VWD is important to provide the best 
therapeutic approaches to these patients.18 However, diagnosis and 
classification of VWD can be complex because of clinical and laboratory 
variability and considerable heterogeneity in its molecular basis.43 VWF plasma 
levels are affected by both inherited and acquired factors as ABO blood group, 
age, illness, pregnancy, and medication, making diagnosis of VWD, particularly 
type 1, difficult.43, 58-61 On the other hand, in some occasions, compound 
heterozygosity for VWF mutations, or presence of mutations in the 
multifunctional domains of the VWF molecule cause pleiotropic effects and 
produce unique phenotype characterizations. Previous studies have 
demonstrated the challenge for a clear discrimination between type 1, 2A and 
2M because of the overlap of these types.62-64 Molecular genetic analysis in the 
last two decades has greatly enhanced our knowledge of the molecular biology 
of the disorder allowing improvement in diagnosis and management of patients 
with VWD. More than 500 different mutations are reported until now in the VWF 
database.1 Nevertheless, for each of the three VWD types important clinical and 
biologic questions currently remain unanswered. Expanding our understanding 
of the molecular basis of VWD helps to find out the pathophysiological 
mechanisms of VWF mutations that will allow a more refined classification of 
VWD and establishment of phenotype-genotype correlations in the future. 
In this study we explored genotype and phenotype characteristics of 114 
patients with VWD with the aim of dissecting the distribution of mutations in 
different types of VWD and correlate them to the clinical disease severity. 
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2.3 Materials and Methods 
 
2.3.1 Patients 
 
A total of 114 patients belonging to 78 families from the Bonn Haemophilia 
Center (80% of patients) and also centers from different regions of Germany 
(20% of patients) with different types of VWD were recruited in our study. The 
patients were classified after laboratory and clinical investigation by the treating 
physician based on ISTH-SSC VWF guidelines.42 Informed consent according 
to the declaration of Helnsinki was obtained from all index patients (IPs) and 
their family members. The majority of individuals collected for this study 
recorded their race/ethnic origin as Caucasian. Whole blood samples from IPs 
and their available family members were collected in both sodium citrate and 
EDTA tubes. 
 
2.3.2 Phenotypic analysis 
 
Coagulation assays: VWF antigen levels were measured using a particle-based 
turbidimetric assay, and procoagulant FVIII:C by an in-house clotting assay. 
Both assays were performed on a BCS XP coagulation analyzer according to 
the manufacturer’s instructions (Siemens Healthcare, Marburg, Germany). The 
VWF:RCo assay and RIPA in platelet-rich plasma with final concentrations of 
ristocetin of 0,5 mg/ml and 1,2 mg/ml were performed using aggregometry-
based in-house assays. The VWF:FVIIIB assay was performed at the source 
clinic attended by the patient. 
Multimer assay: VWF multimer composition was evaluated by sodium dodecyl 
sulfate agarose gel electrophoresis followed by Western blotting and detection 
with rabbit anti-human VWF antibody (Dako, Glostrup, Denmark). The multimers 
were then visualized by luminescence (FluorChem 8000; Alpha Innotech Corp, 
Ca, USA).65 
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2.3.3 VWF analysis 
DNA isolation: Genomic DNA was isolated from peripheral whole blood by 
standard salting out procedure. DNA purity and concentration were determined 
and standardized to 100 ng/µl.66  
DNA sequencing:  Fifty-six primer pairs were used to amplify VWF, including 
exons 2 to 52 and exon/intron boundaries. The promoter region and exon 1 
were also investigated by 8 primer pairs in IPs without any clear causative 
mutation. DNA sequencing was performed on both strands, using the BigDye 
Terminator Cycle Sequencing V1.1 Ready Reaction kit and an automated ABI-
3130 DNA sequencer (Applied Biosystems, CA, USA). Sequence Analysis 
software package (Applied Biosystems, CA, USA) was applied for final 
sequence reading and mutation documentation. 
Any VWF sequence variation that was identified was noted. The ISTH SSC 
VWD homepage (http://vwf.group.shef.ac.uk/index.html accessed May 2012), 
VWFdb Hemobase (http://www.vwf.hemobase.com accessed May 2012) and 
the published literature were checked to see if the variation had been previously 
recorded and if the molecular mechanisms had been elucidated.  SNPdb was 
checked for presence of novel substitutions through NCBI     
(http://www.ncbi.nlm.nih.gov/SNP accessed May 2012). We evaluated the 
likelihood that novel candidate missense mutations could be pathogenic with 
Sorting Intolerant From Tolerant (SIFT, http://sift.jcvi.org accessed January 
2011),67 Polymorphism Phenotyping (PolyPhen,  
http://genetics.bwh.harvard.edu/pph accessed January 2011), and Align GVGD 
(http://agvgd.iarc.fr/agvgd_input.php accessed May 2012). Four splice site 
prediction software programs, Neural Network 
(http://www.fruitfly.org/seq_tools/splice.html accessed January 2011), 
NETGENE2 (http://www.cbs.dtu.dk/services/NetGene2/ accessed January 
2011), WebGene Splice View (http://zeus2.itb.cnr.it/%7Ewebgene/ 
wwwspliceview.html accessed May 2012), and MaxEntScan 
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq_acc.html 
accessed May 2012) were used to investigate the possible pathogenicity of 
potential splice site mutations. 
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MLPA: Investigation for large deletions was performed by MLPA for patients 
without clear causative mutations. Patients were analyzed by MLPA (Kit P011 
and P012, MRC Holland, Amsterdam, The Netherlands) according to the 
manufacturer’s instructions.68 
 
2.3.4 Structure analysis of VWF 
 
The crystallographic models of the recombinant human VWF A2 domain 
(resolution solved to 2.3Å) and the A1 domain/GPIb complex (resolution solved 
to 3.1Å) were downloaded from the Protein Data Bank for viewing, analysis and 
graphical rendering using UCSF Chimera 1.2306.69-71 Ribbon models were 
rendered with the A1/GPIb and A2 domains in different colors. The A1/GPIb 
complex is represented in bicoloured ribbons, the A1 domain turquoise colored 
and the Gp1b domain red colored. The side chains of the native residues at the 
positions of the reported human mutations were depicted as van der Waals 
spheres or sticks. Hydrogen bonds were inferred using the H-bond distance 
calculation algorithm of Mills & Dean (1996) relaxing constraints by 0.4 
angstroms and 20 degrees.72 
 
2.4 Results 
 
One hundred fourteen patients belonging to 78 families were investigated in this 
study. Twenty-eight IPs with low VWF levels met the initial type 1 VWD 
diagnostic criteria according to ISTH-SSC VWF guidelines. The phenotypic 
characteristics of 32 IPs were in agreement with type 2 VWD of which 18 were 
assigned as type 2A, 7 as type 2M, 3 type 2B and 4 type 2N VWD. Eighteen IPs 
were diagnosed with type 3 VWD.  
We identified putative mutations in 66 IPs (84.6%). In total, 68 different 
mutations were detected comprising 37 missense mutations (54.4%), 10 small 
deletions (14.7%), 2 small insertions (2.9%), 7 nonsense mutations (10.3%), 5 
splice-site mutations (7.4%), 6 large deletions (8.8%) (20) and 1 silent mutation 
(1.5%). Of these 68 gene variants, 26 variants (38%) are reported for the first 
time.   
Chapter 2. Distribution of VWF mutations in a cohort of VWD patients 
 
 
- 27 - 
 
 
 
 
2.4.1 Mutations in Type 1 VWD 
 
We identified VWF mutations in 19 (68%) of the 28 studied type 1 VWD 
patients. No VWF mutations were detected in 9 (32%) IPs, presenting with 
VWF:Ag level higher than 30%. In 3 (11%) IPs more than one putative mutation 
was identified. The mutations were distributed along all regions of the VWF 
(Figure 2.1A). However, a substantial number of candidate mutations was 
Figure 2.1. Mutation spectrum analysis of 78 families with VWD. Panels A, C 
and E show distribution of the mutations in relation to the functional domains of the 
VWF protein for type 1, type 2 and type 3 VWD, respectively. In Panel A, the silent 
mutation is considered as a splice site mutation. In Panel C, the mutations for each 
secondary category of type 2 are indicated by different colors, type 2A, type 2B, 
type 2M and type 2N mutations are shown in red, blue, green and yellow, 
respectively. Panels B, D and F show the type and frequency of mutations identified 
in type 1, type 2 and type 3 VWD of our cohort, respectively.  
% represents the frequency of the missense mutations. 
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Table 2.1: Laboratory and genetic data of IPs with type 1 VWD. 
The putative mutations marked with § are novel. 
 † indicates if 2 mutations are on the same allele; ‡ indicates if they are on two different 
alleles and NK if it is not known.  
**: This patient is classified based on collagen binding value (CB: 43%). 
clustered in exon 28 spanning the domains A1, A2, beginning of A3 and end of 
D3 domain.  
A total of 23 putative mutations were identified in the type 1 VWD families 
(Table 2.1). The majority were missense mutations (n=17; 74%), of which 4 
(p.Q499H, p.N857S, p.C2619Y and p.C2676F) are described for the first time 
(Figure 2.1B). Furthermore, 3 of these gene alterations (p.R1205H, p.Y1584C 
and p.S2179F) were repetitive and detected in more than 1 IP. In addition, 3 
splice-site mutations, all affecting the donor splice sites, 2 common small 
deletions and 1 silent mutation were found in our cohort of type 1 VWD patients. 
Interestingly, the same small deletions were detected in type 3 VWD patients 
with another alteration assigning the type 3 VWD (Tables 2.1, 2.3).  
 
 
 
 
 
Patients 
 
Mutation 
Type 
Nucleotide 
exchange 
aa. 
Exchange 
Domain 
 
VWF:Ag 
% 
VWF:Rco 
% 
FVIII:C  
% 
1 Missense c.1497G>C§ p.Q499H D2 44 33 54 
1 Splice site c.1533+1G>T   D2 60 51 83 
1 
Small 
deletion c.2435delC p.P812Rfs*31 D' 43 ** 96 
1 Missense c.2570A>G§ p.N857S D' 56   48 
2 Missense c.3614G>A p.R1205H D3-A1 15, 10 10,10 15,9 
1† Missense c.3686T>G p.V1229G D3-A1 59 52 60 
  Missense c.3692A>C p.N1231T D3-A1       
1 Missense c.4238C>T p.P1413L A1 44 50 55 
2 Missense c.4751A>G p.Y1584C A2 49, 38 42, 30 22,46 
3 Missense c.6536C>T p.S2179F D4-B 20,20,16 14,14,10 26,11,17 
1 Silent c.7464C>T§ p.G2488 C1 11 8 17 
1 Splice site c.7729+5G>A§   C2 65 52 79 
1 Missense c.7856G>A§ p.C2619Y C2 37 43   
1 Missense c.8027G>T§ p.C2676F CK 29 22 58 
1Nk 
Small 
deletion c.2269-2270delCT p.L757Vfs*22 D2-D' 9 4   
  Splice site c.7437+2T>C§   B3-C1       
1 Missense c.4751A>G p.Y1584C A2 77 60 119 
  Missense c.6187C>T p.P2063S D4       
  Missense c.6187C>T p.P2063S D4       
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2.4.2 Mutations in type 2 VWD 
 
Different types of mutations were found in 30 out of 32 type 2 VWD IPs (93.7%). 
In two IPs, diagnosed with type 2A and type 2M based on laboratory data, no 
mutation in VWF was detected.  In total, 27 different VWF variants were 
identified (Table 2.2). The majority (88.1%) of candidate mutations were 
missense substitutions (Figure 2.1D). Six of them (p.R854Q, p.R924Q, 
p.Y1146C, p.C1225G, p.R1306W and p.R1374H) occurred repetitively (Table 
2.2). Missense mutations causing type 2A were predominantly clustered in exon 
28 (Figure 2.1C). Interestingly, we report for the first time two novel missense 
substitutions in domain D4 and B (p.C2085Y and p.C2327W, respectively) 
causing type 2A VWD (Figure 2.1C). Additionally, 1 splice site mutation and 1 
novel large deletion were detected in our cohort of type 2A VWD patients.  
All mutations (6 previously reported missense mutations and 1 novel in-frame 
small deletion) causing type 2M VWD in our cohort of patients were located in 
domain A1 (Figure 2.1C) with the exception of mutation p.R924Q located in 
domain D3. Two of 3 type 2B IPs had 2 different mutations. One of them was 
compound heterozygous for the frequently described mutation p.I1309V and the 
novel substitution p.P1240L, and the other IP was compound heterozygous for 
mutations p.R1306W and p.R854Q showing a combined type 2B and type 2N 
phenotype. The missense mutation p.R854Q was detected in all patients with 
type 2N (either homozygous or compound heterozygous) except for one who 
was homozygous for the missense mutation p.T791M (Table 2.2).  
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Patients 
 
Type 2  
categories 
Mutation 
 Type 
Nucleotide exchange 
 
aa. exchange 
 
Domain 
 
VWF:Ag 
 % 
VWF:Rco 
 % 
FVIII:C 
 % 
4 2A Missense c.3437A>G p.Y1146C D3-A1 17-33 <10-18 21-32 
1 2A Splice site c.3538+1G>A   D3 11 6 10 
2 2A Missense c.3673T>G p.C1225G D3-A1 3 <6 5-35 
  (atypical 2N) Missense c.3673T>G p.C1225G D3-A1       
1 2A Missense c.3863T>G p.L1288R D3-A1 33 15 30 
1 2A Missense c.4571T>G§ p.V1524G A2 90 25 45 
1 2A Missense c.4789C>T p.R1597W A2 25 13 20 
1 2A Missense c.4883T>C p.I1628T A2 20 8 39 
1 2A Large deletion Exons 33-34 deletion§   A3-D4 17 9 1.9 
1 2A Missense c.6254G>A§ p.C2085Y D4 22 13 42 
1 2A Missense c.6981T>G§ p.C2327W B 13 7 22 
1 2A Missense c.4121G>A p.R1374H A1 12 <6 27 
1NK 2A Missense c.4121G>A p.R1374H A1 42 17 46 
    Missense c.2220G>A p.M740I D2-D'       
1‡ 2A Missense c.4121G>A p.R1374H A1 39 <6 22 
    Missense c.2771G>A p.R924Q D3       
1 2B Missense c.3916C>T p.R1306W A1 50 26 57 
1NK 2B Missense c.3916C>T p.R1306W A1 50 24 29 
    Missense c.2561G>A p.R854Q D'       
1‡ 2B Missense c.3925A>G p.I1309V A1 75 56 55 
    Missense c.3719C>T§ p.P1240L D3-A1       
1 2M Missense c.3943C>G p.R1315G A1 25 11 37 
1‡ 2M Small Deletion c.3964_3966delCAC§ p.H1322del A1 21 8 19 
    Missense c.2771G>A p.R924Q D3       
1 2M Missense c.4120C>T p.R1374C A1 22 11 38 
1 2M Missense c.4121G>T p.R1374L A1 20 7 20 
1 2M Missense c.4105T>A p.F1369I A1 30 15 30 
1 2M Missense c.4225G>T p.V1409F A1 27 <6 23 
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Table 2.2: Laboratory and genetic data of IPs with type 2 VWD. 
The putative mutations marked with § are novel.  
† indicates if 2 mutations are on the same allele; ‡ indicates if they are on two different alleles and NK if it is not 
known.  
 
 
 
 
 
 
 
 
 
 
 
Patients 
 
Type 2  
categories 
Mutation 
 Type 
Nucleotide exchange 
 
aa. exchange 
 
Domain 
 
VWF:Ag 
 % 
VWF:Rco 
 % 
FVIII:C 
 % 
1 2N Missense c.2561G>A p.R854Q D' 75 108 40 
    Missense c.2561G>A p.R854Q D'       
1NK 2N Missense c.2561G>A p.R854Q D' 45 40 30 
    Nonsense c.970C>T p.R324* D1-D2       
    Missense c.1001G>A§ p.G334E D1-D2       
1‡ 2N Missense c.2561G>A p.R854Q D' 38 43 9 
    Insertion c.1722_1723insVWFc.1682_1729+33§  p.P574_R575ins D2       
1 2N Missense c.2372C>T p.T791M D' 124 96 3 
    Missense c.2372C>T p.T791M D'       
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2.4.3 Mutations in type 3 VWD 
 
We could detect mutations in 17 of 18 IPs (94.4%). All IPs except one were 
homozygous or compound heterozygous for given mutations (Table 2.3). In 
total, we identified 26 different VWF mutations in type 3 VWD families. The 
majority of mutations (82%) were null mutations (Figure 2.1F) resulting in 
severely decreased VWF:Ag levels. In total, we found 4 previously reported 
missense mutations, 5 large deletions (4 novel), 9 small deletions (5 novel), 1 
insertion, 1 splice site mutation and 6 nonsense mutations (2 novel) (Figure 
2.1E). All small deletions detected in our cohort caused a shift of the reading 
frame and determined a premature termination codon. The small deletions 
c.2435delC and c.7650-7651delCC were located in a stretch of cytosine 
residues while c.7524-7525delGG was in a stretch of guanine residues. One 
previously described cytosine insertion in a stretch of four cytosines (c.7671-
7674) in exon 45 was detected (c.7674_7675insC) in a homozygous status.  
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Table 2.3: Laboratory and genetic data of IPs with type 3 VWD. 
The mutations marked with § are novel.  
† indicates if 2 mutations are on the same allele; ‡ indicates if they are on two different 
alleles and NK if it is not known.  
 
 
2.4.4 Prediction of impact of novel substitutions 
 
The predicted impact of the novel putative mutations was assessed by SIFT, 
PolyPhen, and Align GVGD. Obtained scores are summarized in Table 2.4. 
Both algorithms, SIFT and PolyPhen, showed that all novel missense changes, 
except two, are probably damaging. Align GVGD software predicted all novel 
Patients Mutation type Nucleotide exchange aa exchange Domain VWF:Ag  
% 
VWF:RCO  
% 
FVIII:C  
% 
1‡ Large deletion VWF-del  all domains <6 <6 2 
 Small deletion c.7650_7651delCC§ p.Q2551Afs*16 C2    
1 Large deletion Exons 4-34 del§  D1-D4 <1 <6 2.4 
1NK Large deletion Exons 1-5 del§  Signal-D1 1 5 1.4 
 Missense c.2771G>A p.R924Q D3    
1NK Large deletion Exons 48-52§  C2-CK <3 <10 2.3 
 Small deletion c.2269_2270delCT p.L757Vfs*22 D2-D'    
1 Large deletion Exon 6 del§  D1 <1 <6 5 
 Large deletion Exon 6 del  D1    
1NK Small deletion c.1051delG§ p.V351Cfs*106 D1 <1 <6 2.4 
 Splice site c.8155+3G>A  CK    
1 Small deletion c.1933_1945del§ p.P645Sfs*1 D2 1 <6 1.7 
 Small deletion c.1933_1945del p.P645Sfs*1 D2    
 Nonsense c.6490C>T§ p.Q2164* D4    
1NK Small deletion c.2435delC p.P812Rfs*31 D' <1 <1 <1 
 Nonsense c.1659G>A p.W553* D2    
1 Small deletion c.4570delG p.V1524fs* A2 3 <6 4 
 Small deletion c.4570delG p.V1524fs* A2    
1NK Small deletion c.4944delT p.I1649Sfs*44 A2 <1 <6 4.4 
 Missense c.6911G>A p.C2304Y B    
1‡ Small deletion c.5310delC§ p.I1770Mfs*121 A3 <3 <10 1.8 
 Missense c.4120C>A p.R1374S A1    
1 Small deletion c.7524_7525delGG§ p.D2509Lfs*24 C1 <1 <6 3.7 
 Missense c.8216G>A p.C2739Y CK    
1NK Small Insertion c.7674_7675insC p.S2559Lfs*8 C2 <1 <6 1.4 
 Small Insertion c.7674_7675insC p.S2559Lfs*8 C2    
1 Nonsense c.1093C>T p.R365* D1 1 <6 <10 
 Nonsense c.1093C>T p.R365* D1    
1NK Nonsense c.3360G>A§ p.W1120* D3 4.7 4.5  
 Nonsense c.7300C>T p.R2434* B3-C1    
1 Nonsense c.7176T>G p.Y2393* B 3 <5 4 
 Nonsense c.7176T>G p.Y2393* B    
1 Missense c.8216G>A p.C2739Y CK 3 <6 2 
 Missense c.8216G>A p.C2739Y CK    
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candidate missense mutations except three can most likely interfere with 
function of protein. The variants p.N857S and p.P1240L were assigned as 
tolerable by all three programs. The variant p.P1240L was additionally reported 
in SNPdb as a SNP detected in a normal population. The Align GVGD pointed 
the variation p.Q499H as less likely affective. 
Two novel splice site mutations (c.7437+2 T>C and c.7729+5 G>A) were 
predicted to be deleterious by all four splice-site analysis tools. Moreover, the 
analysis of the silent mutation detected in exon 44 (c.7464C>T, p.G2488) 
showed that it might create a cryptic donor splice site (Table 2.5). 
 
AA 
exchange 
 
Domain 
 
 
VWD 
Type 
 
SIFT 
prediction 
 
PolyPhen 
prediction 
 
AGVGD 
Prediction 
 
p.G334E D1-D2 2N Affect the P.F.  P. D.  Most likely IPF 
p.Q499H D2 1 Affect the P.F.  P.D.  Least likely IPF 
p.N857S D' 1 Tolerated  Benign  Least likely IPF 
p.P1240L D3-A1 2B Tolerated  Benign  Least likely IPF 
p.V1524G A2 2A Affect the P.F.  P. D. likely IPF 
p.C2085Y D4 2A Affect the P.F.  P. D. Most likely IPF 
p.C2327W B 2A Affect the P.F.  P. D. Most likely IPF 
p.C2619Y C2 1 Affect the P.F.  P. D. Most likely IPF 
p.C2676F CK 1 Affect the P.F.  P. D. Most likely IPF 
 
 Table 2.4: Summary of in silico analysis (SIFT, Polyphen and Align GVGD) for 
novel candidate missense mutations.  
P. F.: Protein function, P.D.: Probably damaging, IPF: Interfer with protein function. 
 
 
Nucleotide 
Change 
 
Neural Network 
 
native-mutated 
NetGene2 
 
nativ-mutated 
MaxEntScan  
 
native-mutated 
WebGene Splice 
View 
Native-mutated 
c.7437+2 T>C 
 
0.98-Native DSS 
destroyed 
0.997-Native DSS 
destroyed (0.227) 
11.11-3.36 
 
88-Native DSS 
destroyed 
c.7464 C>T 
(p.G2488) 
 
No P.SS- 
New P.DSS (0.99) 
 
No P.SS (0.849)- 
New P.DSS (1.000) 
 
2.72-10.47 
 
No P.SS- 
New P.DSS (94.) 
 
c.7729+5 G>A 
 
0.97-Native DSS 
destroyed 
0.962-Native DSS 
destroyed (0.378) 
8.37-3.86 
 
86-79 
 
 
Table 2.5: Summary of novel potential splice site mutations prediction. 
DSS: Donor splice site. P.DSS: Potential donor splice site. P.SS: Potential splice site. 
The higher the score, the higher the probability that the sequence is a true splice site.  
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2.4.5 Structure analysis of four missense mutations located in 
A1 and A2 domains of VWF 
 
Structural analysis was done for the novel mutation p.V1524G and 3 other 
recently reported, but not well functionally studied mutations - p.R1315G, 
p.V1409F and p.L1288R (Figure 2.2). Two mutations causing type 2M 
(p.R1315G and p.V1409F) and 1 causing type 2A (p.L1288R) were in domain 
A1, the domain interacting with GPIb receptor on platelets. Investigation of the 
local environment for these mutant residues identifies domain instability induced 
by side chain clashes/disruption of hydrogen bonds as their primary causative 
influence (Figure 2.2A-C). The mutations p.R1315G and p.V1409F also have a 
negative influence on the binding of A1 domain to the GPIb molecule. One other 
mutation, p.V1524G (causing type2A VWD) in the A2 domain, results in an 
easier access of the ADAMTS13 cleavage site by facilitating the unfolding of 
this domain (Figure 2.2D). 
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Figure 2.2. Close-up views of the local molecular environments of four human 
VWFA1 and VWFA2 domain missense mutations depicted on structural models 
of VWFA1 /GPIb and VWFA2 domains (PDB ID: 1M10; resolution: 3.10A° and PDB 
ID: 1AUQ; resolution: 2.30A° respectively).   
The figure is divided up into four panels representing four different mutations. Panel A, 
B and C depict mutations in VWFA1 domain while Panel D corresponds to mutation in 
VWFA2 domain. Panel A. The panel is split into three images. The top image depicts 
the interface between the VWFA1 domain and GPIb molecule. The contacts (H-bonds) 
across the interface are represented by red lines. The affected residue is depicted as a 
dark blue CPK sphere. The image on the left shows the H-bonds formed by the wild 
type p.R1315 residue. The image on the right shows the H-bonds formed by the 
mutated p.G1315 residue. Both residues are depicted as ball and stick models. No 
structure is apparent for the side-chain of glycine since it is a single hydrogen atom (not 
resolved in the 3.10 Å X-ray crystallographic data). The backbone of the VWFA1 
domain and GPIb molecule are represented as grey ribbons respectively. The effective 
surface of these residues is depicted in magenta. Panel B. The panel is split into two 
images. The image on the left shows the wild type p.V1409 residue and the image on 
the right shows the mutated p.F1409 residue. The backbone of the VWFA1 domain 
and GPIb molecule are represented as grey ribbons. The residues are represented as 
CPK spheres. The red lines which are indicated with a black arrow depict clashes with 
p.I617 and p.A618. Panel C. The panel is split into two images. The residues of interest 
are represented as dark blue sticks. The left image depicts local environment of the 
wild type p.L1288 residue. The positive charge on the residues proximal to the affected 
p.L1288 are represented in red surface colors while the neutral charge of the p.L1288 
residue is depicted in green. The right image represents the mutated p.R1288 residue 
which brings another positive charge in proximity to the other two charged residues 
giving a reddish hue to the original green colored surface. Panel D p.V1524 (red sticks) 
is shown near the hydrophobic plug formed by the vicinal disulphides (green ribbon and 
stick) and 8 other hydrophilic residues (deep blue sticks). The backbone of the VWFA1 
domain is represented as a turquoise ribbon. 
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2.5 Discussion 
 
In the present cohort, we investigated VWD patients for variations within VWF 
to elucidate the molecular basis for each type in order to enhance 
understanding of the disorder. The majority of mutant alleles (74% vs 88.1%) 
identified in our patients with type 1 and type 2 VWD were missense mutations, 
while null alleles were predominant (82%) in patients with type 3 VWD (Figure 
2.1 B, D and F). The sequence variants identified in our cohort of type 1 and 
type 3 VWD patients spread throughout the whole VWF, but as expected, were 
confined to a particular region of the VWF in the different types of our patients 
with type 2 VWD (Figure 2.1A, C and E). These findings are in line with 
previous reports.1, 51, 73-75 
The VWF:Ag level was variable in our cohort of type 1 VWD patients. A mean 
VWF:Ag of 39.5% was registered, ranging from 9% to 77%. Our data showed a 
correlation between VWF:Ag level and mutation detection rate. In all patients 
with type 1 VWD and VWF:Ag level less than 30% mutations were identified. In 
contrast, in only 53% of patients a mutation was detected when VWF:Ag was 
higher than 37%. Our data supported the finding of other groups,73, 74 indicating 
that in milder cases of VWD, the genetic determinants are more complex and 
might involve other factors outside the VWF. In our study, VWD type 1 patients 
bearing p.S2179F and p.R1205H expressed the lowest VWF antigen levels (10-
20%) compared to the antigen levels of patients with other missense mutations. 
These data are in concordance with the literature.62-64, 76, 77 
Although the pattern of mutations found in type 3 VWD patients was similar to 
previous studies, only few of the mutations identified so far have been found 
repetitively in analogous studies from different populations.78-80 The presence of 
11 novel mutations in 17 IPs diagnosed as type 3 VWD in our cohort shows a 
high degree of genetic heterogeneity in the molecular pathology of type 3 VWD.  
VWD is known for a high degree of variability in clinical presentation and a 
considerable heterogeneity of its molecular basis. It has been shown that within 
the phenotypic classification of VWD, variations within a single mutation can be 
responsible for different types of the disease. Thus, some substitutions are 
discussed controversially. The missense mutations affecting p.R1374 is 
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presented with different variants depending on the nucleotide substitution. In 
our study the variant p.R1374H led to type 2A VWD. Two other variants of 
p.R1374, p.R1374L and p.R1374C, were considered to be responsible for type 
2M VWD (Table 2.2). Although the ISTH registry of VWD assigns these variants 
as unclassified (U), they have been classified by several investigators into 
different VWD types due to the patient´s pleiotropic phenotype.1, 75, 81-83 
In some cases an equal mutation contributes to expression of different 
phenotypes. The variant p.R924Q is listed as a polymorphism, as a type 2N 
mutation and also as a type 1 mutation in the ISTH SSC VWF database. In our 
study this gene alteration was associated with type 2M (2 patients) and type 3 
(1 Patient) VWD. However, p.R924Q was found as a second causative mutation 
in a patient with type 3 VWD. Berber et al. demonstrated through in vitro 
expression studies that the p.R924Q variation does not significantly affect 
biosynthesis of VWF, but they suggested that this variant allele may mark a null 
allele in some instances.84 Hickson et al also reported that its inheritance alone 
may be insufficient for VWD diagnosis, but it appears to be associated with a 
further VWF level reduction in individuals with a second VWF mutation.85 
Therefore, we cannot exclude the possibility of a second mutation in intronic 
regions or outside of the VWF for the IP with type 3 VWD. 
The variant p.P2063S is listed in the ISTH SSC VWF database as a type 3 
mutation, and it has been identified in Canadian and Spanish populations in 
type 1 VWD patients.63, 82 Moreover, p.P2063S is found in a Spanish population 
in compound heterozygous state with p.V1409F in a type 2M patient with Blood 
group A, VWF:Ag 9% and VWF:RCo 3%.82 The patient heterozygous for 
p.V1409F variant with Blood group A classified as type 2M in our cohort shows 
VWF:Ag 27%, VWF:RCo <6. Comparison of the laboratory data of these 2 
patients indicates a possible influence of p.P2063S as a second variant for the 
quantitative defect in the Spanish patient.  However, the functional study of this 
substitution by Eikenboom et al. showed that p.P2063S is possibly a 
polymorphism.86 In our cohort, p.P2063S was detected in homozygous state in 
combination with p.Y1584C in a patient with type 1 VWD exhibiting VWF:Ag 
level of 77% and VWF:RCo of 60%. Since p.Y1584C is also known as a variant 
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with incomplete penetrance, determination of causative mutation explaining the 
phenotype of this patient is ambiguous. 
An interesting mutation is p.C1225G listed as a type 2N mutation in the ISTH 
SSc database. In our cohort the patients carrying p.C1225G are classified as 
type 2A VWD owing to relative reduction of big multimers and normal values of 
VWF:FVIIIB (in one patient). However, Allen et al. classified this mutation as an 
atypical type 2N mutation.87 They discovered by in-vitro expression of the 
recombinant VWF that this mutation affects the level of secreted VWF, the 
binding of VWF to factor VIII and the ability of VWF to form multimers. The 
pleiotropic effects of this mutation on the VWF molecule make its classification 
complicated.  
The novel variant p.N857S is predicted to be benign by all predictive tools, but it 
is one of the twelve N-linked glycosylation sites of the mature VWF protein.88 
Therefore, its causality cannot be excluded prior to expression studies. In total, 
we found 5 splice site mutations and 1 silent mutation. The previous studies 
have proved the causality of 3 of these splice site mutations by mRNA 
analysis.77, 89 Both, two novel splice site mutations and 1 novel silent mutation, 
were predicted to be causative by all splice-site analysis tools used in our study. 
 
Structural interpretation  
 
The A1 domain structure can be divided into six unique faces or fronts.70 The 
p.R1315 residue is located on a beta strand from the previously defined “lower 
face”. It is part of an elaborate set of domain stabilizing salt bridge networks and 
forms hydrogen bonds with an adjacent strand and a loop. Mutation to a much 
smaller glycine residue would result in the disruption of these H-bonds resulting 
in domain instability (Figure 2.2A). Additionally, since the confirmation of this 
region is essential for binding to platelets, the altered domain structure would 
also negatively influence the same. The mutation p.V1409F is also situated in 
proximity of this surface and the resulting longer Phenylalanine side chain may 
result in side chain clashes and disturb the binding of this surface to the Gp1b 
molecule (Figure 2.2B). The mutation p.L1288R is located on the previously 
defined “upper face” of the A1 domain which is uncharged surface of approx. 
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20A° diameter with charged residues only at the periphery.70 The only charged 
residues on this surface are the p.R1287 and p.H1419 (Figure 2.2C). The 
mutation of p.L1288 to a large positively charged arginine residue over this 
surface will destabilize this region and result in an unstable molecule. The 
mutation also disrupts a domain stabilizing salt bridge network (loss of H-bonds 
to a connecting loop and helix) resulting in an unstable A1 domain.   
The shear induced unfolding of the VWF A2 domain to expose the p.Y1605-
p.M1606 ADAMTS13 cleavage site, is a well investigated phenomena.90 In the 
A2 domain crystal structure 3GXB, the p.V1524 residue is proximal to a 
hydrophobic plug formed by the hydrophobic interaction of the vicinal disulfides 
and eight residues which forms the first high energy barrier against the 
unfolding (entry of water molecule) of the A2 domain prior to the final rate 
limiting step (Figure 2.2D).90 The mutant polar p.G1524 residue in the proximity 
of this hydrophobic plug will reduce the energy barrier for this step and result in 
easier access to the ADAMTS13 cleavage site. 
In conclusion, our study extends the mutational spectrum of VWF, and improves 
the knowledge on the genetic basis of different types of VWD. This data 
provides the opportunity to possibly design functional studies to understand 
molecular mechanisms underlying this disease and establish genotype-
phenotype correlations for proper classification and improving clinical 
management. Additionally, our study also shows that the combination of 
mutations causing different types of VWD within one patient causes complex 
phenotypes. Finally, the availability of well defined crystal structures for some of 
the VWF domains is useful in understanding the molecular etiology of some of 
the variants and their impact on protein structure. The understanding of the 
molecular etiology of these variants is crucial in determining their causality and 
therefore establishing their credentials as mutations or mere neutral 
polymorphisms.  
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Chapter 3 
 
Large deletions identified in patients with von 
Willebrand disease using multiple ligation-dependent 
probe amplification 
 
Adapted from 
Yadegari H., Driesen J., Hass M., Budde U., ,Pavlova A., and Oldenburg J. 
Journal of Thrombosis and haemostasis. 2011;9:1083-1086 
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3.1 Abstract 
 
Large deletions are considered as being a rare cause of VWD. In the VWF 
database only 12 large deletions are reported ranging in size from a single exon 
to the entire gene. The aim of our study was screening for large deletions of 
VWF in VWD patients where direct sequencing of VWF failed to reveal 
causative VWF gene mutations or showed homozygousity for a given mutation 
and polymorphisms. Twenty-three patients were investigated, including 11 
patients with type 1, 3 patients with type 2 and 9 patients with type 3 VWD. 
Genomic DNA was isolated by standard methods and investigation for large 
deletions was performed by MLPA. Six large deletions were identified in our 
cohort of which five were not previously described. Five large gene deletions 
were detected in patients with type 3 VWD and one in type 2 VWD. A 
homozygous deletion of exon 6 was identified in 2 patients with type 3 VWD 
belonging to the same family. The deletion segregates within the family and was 
detected in another four family members in heterozygous state. The deletions 
spanning the exons 1-5, whole gene and exons 48-52 were combined with a 
second mutation affecting the other allele – a missense mutation, a small 
deletion in exon 45, or a small deletion in exon 17, respectively. In the patient 
with the heterozygous large deletion of exon 4-34, no second mutation was 
identified. Interestingly a large deletion of exons 33-34 of VWF along with a 
missense mutation in FVIII gene (F8) was detected in a combined type 2A 
VWD/hemophilia A patient. Our results indicate that investigation for presence 
of heterozygous large deletions should be taken into consideration when no 
causative mutations are identified, or homozygous polymorphisms and 
homozygous mutations are detected. 
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3.2 Introduction 
 
A large diversity of mutations as missense, nonsense and splice site mutations, 
small deletions/insertions and large deletions has been reported in the VWF 
gene database.91 Large deletions are regarded as being a rare cause of VWD, 
usually resulting in a complete lack of VWF protein.10 Twelve large deletions, 
ranging in size from a single exon to the entire gene, responsible for type 3 
VWD are reported up to now. In some instances, large deletions represent a 
cause of both types of 1 and 3 VWD.92 Interestingly, a large deletion covering all 
VWF A domains has been described for type 2A.91 An Alu repeat-mediated 
unequal homologous recombination event is the most common mechanism 
involved in large deletions in the VWF.55, 93, 94 There are approximately 100000 
Alu repeats in the human genome, and these have been repeatedly involved in 
the generation of deletion mutations. At least 14 Alu sequences have been 
identified in VWF .95 
Large deletions are particularly difficult to detect in autosomal conditions, where 
the failure to amplify one VWF allele can be masked by amplification of the 
second allele. Thus, false-negative results in carriers of heterozygous large 
deletions can be obtained. Methods based on gene dosage analysis such as 
MLPA have been successfully applied for detection of heterozygous deletions.95 
The aim of our study was to determine the molecular basis of VWD in patients, 
where direct sequencing of VWF gene failed to reveal causative mutations. 
 
3.3 Method and materials 
 
Seventy nine IPs with different types of VWD from the Bonn Haemophilia 
Center have been included in our investigation. All patients gave informed 
consent according to the declaration of Helsinki. Genomic DNA was isolated by 
standard methods. Mutational screening analysis was carried out by direct 
sequencing of exons 2 to 52 including exon/intron boundaries of the VWF gene 
for all patients with VWD. We could not detect causative mutations in 11 IPs 
with type 1 and in 3 patients with type 2 VWD, which were further investigated 
for the presence of large deletions. Patients with type 3 VWD, in whom no 
Chapter 3. Identification of large deletions in VWD  
 
- 44 - 
mutation was found (1 patient), or a homozygous causative gene alteration 
together with homozygous known polymorphisms were identified (4 patients), 
as well as patients with only one heterozygous genetic defect discordant to the 
severity of the disease (4 patients) were additionally tested for the presence of a 
large deletion. All 23 patients were analyzed by MLPA (Kit P011 and P012, 
MRC Holland, Amsterdam, The Netherlands) according to the manufacturer’s 
instructions. The PCR products were run on an ABI PRISM 3130XL sequencer 
with the GeneScan 500 LIZ size standard and analyzed by GeneMapper 
Software 5.0 (Applied Biosystems). Dosage analysis based on a comparison 
between deleted and reference wild-type DNA samples were performed by the 
Excel-based software Coffalyser V9.4 (MRC-Holland).  
 
3.4 Results and Discussion 
 
In total, 6 large deletions (5 novel) were identified in our cohort of patients with 
VWD. Five large gene alterations were detected in patients with type 3 VWD 
and one account for type 2 VWD (Table 3.1).   
 
 
 
Table 3.1. Laboratory phenotype and molecular genetic analyses of patients with 
VWD. 
 
*= The patient IP-6 had an additional mutation in the F8 (Asn2129Ser) 
 
 
Our first patient presented with homozygous large deletion of exon 6, detected 
directly by lack of amplification product of exon 6 and confirmed by MLPA 
(Table 3.1, Figure 3.1A). This patient exhibited severe bleeding symptoms 
  vWF:Ag vWF:RCo FVIII:C Allele 1 Allele 2  Type VWD 
  (%) (%) (%) Exon aa substitution Zygosity     
IP-1 <1 <6 5   Deletion exon 6 homozygous    Deletion exon     6  Type 3 VWD 
IP-2 <6 <6 2 45 p.Gln2551AlafsX16 homozygous    Whole gene deletion  Type 3 VWD 
IP-3 1 5 1,4 21 p.Arg 924Gln heterozygou   Deletion exons  1-5  Type 3 VWD 
IP-4 3   17 p.Leu 757ValfsX22 heterozygou   Deletion exons 48-52  Type 3 VWD 
IP-5 <1 <6 2,4   No mutation     Deletion exons   4-34  Type 3 VWD 
IP-6 17 9 1,9*   No mutation     Deletion exons 33-34  Type 2 VWD 
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subjecting him to prophylactic treatment. The serological measurements of 
VWF antigen (VWF:Ag) of <1%,  VWF ristocetin-cofactor activity  (VWF:RCo) of 
<6% and factor VIII activity (FVIII:C) of 5% confirmed the VWD type 3. The 
homozygous status of the deletion was due to the consanguineous marriage in 
the family. The deletion segregates within the family and was detected in 
another 6 family members – in 5 as a heterozygous gene defect and in one in 
homozygous state. All heterozygous family members showed reduced values of 
VWF:Ag ranging from 49% to 84%, VWF:RCo – 48-76% and FVIII:C 70-83%.  
All patients experienced mild bleeding symptoms such as epistaxis and 
cutaneous hemorrhages that meet the criteria of mild type 1 VWD. The 
sequencing results of VWF gene revealed a homozygous small deletion in exon 
45 (p.Gln2551AlafsX16) of IP-2 (Table 3.1). As consanguinity was excluded and 
the laboratory data were susceptible to type 3 VWD (VWF:Ag <6%, VWF:RCo 
<6% and FVIII:C 2%), MLPA was performed (Table 3.1). A whole gene deletion 
was detected, which clearly explained the pseudo-homozygous presentation of 
the small deletion and corresponds to the type 3 VWD (Figure 3.1B). Clinically, 
repetitive severe epistaxis and subcutaneous haematomas were observed. The 
mother reported no history of bleeding episodes and the laboratory data were in 
the border line of the normal range. Only the heterozygous small deletion was 
proven after sequencing of the VWF. 
The next two patients in our cohort (IP-3 and IP-4) presented with type 3 VWD 
due to compound heterozygous mutations. In the first case, a missense 
mutation (p.Arg924Gln) was combined with a large deletion spanning exons 1-5 
(Table 3.1, Figure 1.3C). We expect the Arg924Gln and the large deletion to be 
compound heterozygous, because of the VWD type 3 phenotype and because 
no other mutation could be found. However, as no further relatives have been 
available to determine the phase, it cannot be excluded that both mutations are 
located on the same allele and a so far not detected mutation is affecting the 
second allele. Clinical data in this patient showed severe bleeding episodes 
including repetitive epistaxis, cutaneous and muscles haematomas, postpartum 
bleedings and a heavy menorrhagia, subjecting her to a prophylactic treatment.  
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Figure 3.1 A-F. Multiple ligation-dependent probe amplification (MLPA) of 6 index 
patients (IPs). The X-axis represents the probes of each exon of VWF and control 
probes (C). Probes of 52 exons of VWF are divided in 2 different probemixes; Mix 1 
(Left figures) and Mix 2 (right figures); there are two probes for the exons 2, 6, 28, 47. 
The heterozygous deleted exons are presented with half size of the peaks.  
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A heterozygous small deletion (p.Leu 757ValfsX22) together with a large 
deletion of exons 48-52 was detected in the IP-4 (Table 3.1, Figure 3.1D). 
The IP-5 showed evidence of severe type 3 VWD. Numerous epistaxis, oral 
cavity bleedings, gastrointestinal bleedings and haematomas were reported by 
this patient. Laboratory data proved type 3 VWD (VWF:Ag <1%, VWF:RCo <6% 
and FVIII:C 2,4%). Surprisingly, the genetic investigation revealed only a 
heterozygous large deletion of exons 4-34 (Table 3.1, Figure 3.1E). Since this 
single defect could not explain the severe clinical picture, it could be speculated 
that another genetic alteration, affecting either structures outside the VWF or 
inside the VWF intronic region are involved. A second possibility is that two 
separate large deletions spanning together exons 4-34 affect both alleles 
without overlapping each other. Unfortunately, the parents were not available to 
prove this hypothesis.  
An interesting case was IP-6 where we present combined VWD and 
haemophilia A (Figure 3.2a). The patient’s laboratory data showed reduced 
VWF:Ag (17%), VWF:RCo (9%) and FVIII:C (1,9%). The genetic analyses of F8 
showed a missense mutation in exon 23, Asn2129Ser. This mutation is 
localized in the FVIII C1 domain and leads to impairment of FVIII binding to 
VWF.96  
The mother was a carrier of the same gene defect although no bleeding history 
is reported in any family member from her site. The VWF:Ag and  VWF:RCo 
were in the normal range. The patient’s father displayed a significant decrease 
in VWF:Ag and VWF:RCo - 13% and 7%, respectively , FVIII: C of 18,5% and 
the VWF:RCo/ VWF:Ag ratio of 0,5 pointing out to type 2 VWD. The VWF 
multimer analyses depict a reduction of large multimers (located in the black 
box) typical for type 2A VWD (Figure 3.2b).  
The sequencing of the VWF of the father of IP-6 showed no genetic alteration 
and MLPA revealed a large deletion of exons 33-34 (Figure 1.3F and Figure 
3.2c).This genetic defect segregates in the family and was proven in 5 other 
members, including the IP-6 (Figure 3.2a). Clinically, the patient experienced 
bleedings in the oral cavity, ankle joint and haematomas. All bleeding events in 
the IP were presented with stronger severity compared to the one of his brother 
and father who did not bear the F8 mutation but only the large deletion in VWF. 
The majority of mutations responsible for dominant type 2 VWD are missense 
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substitutions. Only one large deletion removing domains A1, A2 and A3 of VWF 
was previously reported in a patient with type 2A VWD.97 Casari et al. showed 
in their study the mechanism of this dominant-negative large deletion that can 
cause severe type 2 VWD through in vitro coexpression of the wilde-type and 
the in-frame deleted VWF. They discovered that the altered VWF formed 
heterodimers and heterotetramers with wild-type VWF and these heterodimers 
act as terminators of the multimerization process in the Golgi compartment.98 
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Figure 3.2 
(a) Pedigree of a family with deletion of exons 33-34 of the VWF gene. (b) Results of 
multimer analysis of three family members that show reduction of large VWF 
multimers, marked with the black box, compared to pooled normal plasma. (c) MLPA 
of IP-6. The deleted exons 33 and 34 present with half size of the peaks. 
 
= VWD affected male 
= VWD unaffected male 
= VWD unaffected female 
= haemophilia A carrier female 
= combined VWD and haemophilia A male 
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No large deletion was detected in 11 index patients with type 1 VWD in whom 
VWF antigen level was more than 33 IU/dL. Previous studies have reported that 
VWF levels below the reference range but above 30IU/dL may often not be in 
linkage to the VWF locus.42 , 99 
In conclusion, our results indicate that large deletions should be taken into 
consideration for the diagnosis of type 3 VWD especially in patients without two 
clear causative mutations. The possibility of a large deletion should always be 
taken into consideration if sequencing results reveal the presence of 
homozygous polymorphisms or a homozygous mutation. Moreover, not only 
type 3 VWD patients but also patients diagnosed to have type 2 VWD in which 
no VWF mutation could be identified, should be analyzed for the presence of 
large deletions. Despite the fact that no large deletions were detected in 
patients with type 1 VWD in our study, we propose to investigate these patients 
for the presence of possible heterozygous large deletions when no causative 
mutations are identified. Finally, the MLPA assay is a rapid, simple and robust 
method for the routine diagnosis of large deletions.  
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Chapter 4 
 
Insights into pathological mechanisms of 
missense mutations in C-terminal domains of 
von Willebrand factor causing qualitative or 
quantitative von Willebrand disease 
 
 
Adapted from 
Yadegari H., Driesen J., Pavlova A., Biswas A., Ivaskevicius V., Klamroth R., 
and Oldenburg J., 
Accepted to be published in Haematologica [In Press] 
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4.1 Abstract 
 
 
The carboxy-terminal domains of VWF, D4-CK, are cysteine rich, implying their 
structural importance. The present study characterized the impact of five 
cysteine missense mutations residing in D4-CK domains on conformation and 
biosynthesis of VWF. These variants were identified as heterozygous in type 1 
(p.Cys2619Tyr and p.Cys2676Phe), type 2A (p.Cys2085Tyr and p.Cys2327Trp) 
and as compound heterozygous in type 3 (p.Cys2283Arg) VWD. Transient 
expression of human cell lines with wild-type or mutant VWF constructs was 
performed. Quantitative and qualitative assessment of mutated recombinant 
VWF was done in comparison with recombinant wild-type VWF. Storage of 
VWF in pseudo-Weible-Palade bodies was studied with confocal microscopy. 
Structural impact of the mutations was analyzed by homology modeling. 
Homozygous expressions showed that these mutations caused defects in 
multimerization, elongation of pseudo-Weible-Palade and consequently 
secretion of VWF. Co-expressions of wild-type VWF and p.Cys2085Tyr, 
p.Cys2327Trp and p.Cys2283Arg demonstrated defect in multimer assembly, 
suggesting a new pathologic mechanism for dominant type 2A VWD due to 
mutations in D4 and B domains. Structural analysis revealed that mutations 
p.Cys2283Arg, p.Cys2619Tyr and p.Cys2676Phe disrupted intra-domain 
disulfide bonds, whereas p.Cys2327Trp might affect an inter-domain disulfide 
bond. The p.Cys2327Trp variant is distinguished from the other mutants by an 
electrophoretic mobility shift of the multimer bands. The results highlight the 
importance of cysteine residues within the C-terminal of VWF on structural 
conformation of protein and consequently multimerization, storage, and 
secretion of VWF. 
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4.2 Introduction 
 
Types 1 and 3 VWD are characterized by quantitative deficiencies of VWF. This 
can  resulte from relative (type 1) or absolute (type 3) deficiency in VWF 
production due to impaired synthesis, secretion, or half-life of the molecule.3, 18, 
100
 The VWD type 2A, characterized by the absence of HMWM and decreased 
platelet-dependent function, is the most common form of VWD type 2.51, 59 The 
loss of HMWM in type 2A VWD results from either mutations that impair 
assembly and secretion of VWF multimers or variants that increased 
susceptibility to proteolytic cleavage by ADAMTS13. 9, 101, 102 
The pre-pro-VWF precursor comprises of a signal peptide and repeated 
domains arranged in the order D1-D2-D′-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-
CK. In the ER, pro-VWF assembles into dimers through disulfide bonds 
between CK domains, and is then transported to the TGN. There the dimers 
assemble into multimers by N-terminal disulfide bonds aligned with formation of 
helical tubules in nascent WPB.27, 32 The domains may be characterized as 
functional or structural, depending on whether they have specific functions in 
haemostasis or in forming ultralong concatamers. Although carboxy-terminal (C-
terminal) of VWF, including D4, B and C domains, is a cysteine-rich area, which 
may imply structural importance, no particular function for most of these 
domains is assigned.16   Recently, the classical annotation of the C-terminal 
domain has been updated by Zhou et al., where the previous B and C regions 
of VWF are re-annotated as 6 tandem von Willebrand C (VWC) and VWC-like 
domains, C1-C6.19 Additionally,  it has been demonstrated that the VWF C-
terminals zip up and form a structure resembling a bouquet of flowers, where 
the  A2, A3, and D4 domains comprise the flowers part and the six VWC 
domains configure the stem.19, 31  
In this study we analyzed five different VWF mutations, affecting cysteine amino 
acids in the D4, B, C2 and N- terminal of CK domains, four of which have been 
previously reported in our work.103 Interestingly, these gene alterations were 
associated with either quantitative (types 1 and 3) or qualitative VWD (type 2A). 
The mutations have been transiently expressed in vitro, and their effect on the 
multimer assembly, biogenesis of WPB and secretion has been characterized. 
Possible structural impact of these cysteine mutations was additionally studied 
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by homology modeling. The results of the present study expand our 
understanding of the pathophysiological mechanisms of C-terminal domains 
VWF mutations which will help in establishment of phenotype-genotype 
correlations. 
 
4.3 Materials and Methods 
 
4.3.1 Patients 
 
Five patients, diagnosed with VWD (2 patients with type 1, 2 patients with type 
2A and 1 with type 3) were included in the study. Bleeding severity was 
quantified by the bleeding score (BS) calculated on the basis of condensed 
MCMDM -1 VWD questionnaire.104 This study was approved by the local ethics 
committee and informed consent was obtained from all patients (vote 091/09). 
 
Coagulation and multimer analysis 
 
Laboratory investigation of VWF antigen (VWF:Ag), VWF ristocetin cofactor 
activity (VWF:RCo), FVIII coagulant activity (FVIII:C) and VWF multimers (1.2% 
[w/v] and 1,6% [w/v] agarose gels) was performed.60, 103 VWF multimer profiles 
were classified as normal or abnormal.  
 
Mutation detection 
 
All mutations were identified by direct sequencing of VWF coding region, exon–
intron boundaries and 5’ and 3’ non-coding regions.103 
 
4.3.2 Expression studies 
 
Plasmid constructs 
 
Plasmid pMT2-VWF containing the human full-length wild-type (WT) VWF 
cDNA was kindly provided by Professor Schneppenheim (Department of 
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Pediatric Hematology and Oncology, University Medical Center Hamburg-
Eppendorf, Hamburg, Germany). The mutant constructs were generated using 
a QuickChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, 
USA). The sequences of all constructs were verified by DNA sequencing.  
 
Cell culture and transfection 
 
Human embryonic kidney cell lines (HEK 293T; DSMZ, Braunschweig, 
Germany) were used to evaluate the secretion and intracellular retention of WT 
and mutants recombinant VWF (rVWF). HEK293 cell lines (DSMZ, 
Braunschweig, Germany) were used to analyze the intracellular location of VWF 
by confocal immunofluorescence microscopy.  Both cell lines were cultured in 
Dulbecco’s modified Eagel medium (DMEM) containing 4.5g L¯1 glucose and 
2mM L-glutamine supplemented with  10% (v/v) fetal bovine serum, 100IU mL¯1 
penicillin, 100 µg mL¯1  streptomycin and 0.25 UG/ML Fungizone (all reagents 
supplied by Life Technologies, CA, USA) at 37°C in 5% CO2 atmosphere. 
Cells were transiently transfected with 8µg of WT-VWF or mutated VWF 
constructs using liposomal transfer (Lipofectamine 2000; Life Technologies, CA, 
USA) according to the manufacturer’s instructions. Co-transfections were 
performed using an equal amount of WT and mutant vectors (4 µg each of WT 
and mutant DNA) to reproduce the patients’ heterozygous state. Seventy-two 
hours after transfection of HEK293T cells, supernatants were collected and 
cells were lysed for analysis of intracellular VWF. VWF secreted in the medium 
was concentrated on Amicon Centrifugal 50K filter devices (Millipore, USA) to 
one-forth of the original volume before subsequent analysis. The transfected 
cells were lysed by 3 rounds of freezing (-80˚C) and thawing in lysis buffer 
(0.1M Tris/HCl pH 8.0; 0.6 [v/v] Triton X-100).105 
 
4.3.3 Quantitative and qualitative analysis of rVWF 
 
 The amount of VWF:Ag secreted into the medium and VWF:Ag present in the 
cellular lysate were determined, and the values were expressed as a 
percentage of the corresponding WT recombinant VWF. Activity of secreted 
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rVWF was assessed by binding to platelet GPIb, collagen type III (VWF:CB), 
and VWF:RCo. The VWF activities were expressed as ratios to secreted VWF. 
VWF:GPIb binding was determined using a particle enhanced assay (Siemens 
Healthcare, Marburg, Germany) and VWF:CB was assessed by ELISA method 
(Technoclone, Vienna, Austria) according to the manufacturer’s instructions. 
Comparison between the mean values of the groups was performed with the 
Student t-test. Multimer analysis of concentrated secreted rVWF was performed 
as described above.  
 
4.3.4 ADAMTS13 assay 
 
To assess the susceptibility of mutants of VWF to proteolysis, full-length WT 
and mutated rVWF (6µg/ml) were cleaved by 3µg/ml of recombinant 
ADAMTS13 (R&D systems, USA) in the presence of 1.5M urea at 37˚ C for 2 
hours following the manufacturer’s instructions. The multimer patterns of 
mutated and rVWF-WT were visually compared on agarose gel electrophoresis 
after ADAMTS13 digestion.  
 
4.3.5 Immunofluorescence analysis 
 
HEK293 cells were grown on gelatin pre-coated glass coverslips in 24-well 
plates. Cells were fixed 48 hr after transfection by 4% (w/v) paraformaldehyde 
in PBS, blocked with 0.1% (v/v) Triton-X 100 in PBS azide supplemented with 
10% (v/v) FBS. Cells were incubated with first antibodies for 2 hr and then with 
fluorescence-conjugated secondary antibodies for 1 hr. Polyclonal sheep to 
human VWF (abcam, England) and rabbit anti–human VWF antibodies (Dako, 
Glostrup, Denmark) were used to visualize VWF. Monoclonal anti-GM130 (BD 
Bioscience, CA) and polyclonal rabbit anti-human TGN46 (Sigma-Aldrich, USA) 
were used to stain cis- and trans-Golgi networks, respectively.106 To visualize 
the endoplasmic reticulum (ER), the HEK293 cells were prepared and stained 
with rabbit anti-human protein-disulfide isomerase (PDI) antibody using 
SelectFX® Endoplasmic Reticulum Labeling kit (Life Technologies, CA, USA) 
according to the manufacturer’s instructions. Secondary antibodies were 
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conjugated with either AlexaFluor-488 or AlexaFluor-594 (Life Technologies, 
CA, USA). The coverslips were mounted onto microscope slides with 
Vectorshield (Vector Labs, Burlingame, CA, USA) and analyzed with the 
Olympus Fluo View FV1000 or Leica SL confocal microscope.  
 
4.3.6 Structure analysis  
 
Homology modeling of VWF C1, C5, C6 domains 
 
Homology models for the C1, C5, and C6 domains were constructed using 
various software packages. The domain boundaries for C1, C5, and C6 
domains were based on domain annotations from a recently published article.19 
The sequences for the respective domains were from the VWF (Accession 
number P04275) full length sequence. Templates for each of the domains were 
searched on the LOMETS server from Zhang.107 Close packed alignments 
(using the conserved cysteines as guideposts) were generated between the 
best LOMETS templates and the original domain sequences using Jalview. The 
alignments as well as the templates were entered into YASARA version 
12.8.6108 to generate full-length models. The resulting models were further 
refined by a 500ps MD simulation (AMBER03 force field) in YASARA version 
12.8.6. The models with the lowest force field energies were chosen as the final 
models for the respective domains. The stereochemical quality of these models 
were checked on the MOLPROBITY server 
[http://molprobity.biochem.duke.edu/;accessed between 15.07.2012 and 
15.09.2012].109 The monomer models were run on the online server CLUSPRO 
in dimer mode (http://cluspro.bu.edu/home.php;accessed between 15.08.2012 
and 15.10.2012) and the best dimers were chosen based on cluster size for 
further interface analysis.110 Impact of mutation on folding was calculated using 
the FOLDX plugin incorporated in YASARA version 12.8.6.111 
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Molecular models of the VWF mutations 
 
The missense mutations were modeled on the final refined wild-type VWF 
domain structures. The mutant structure was optimized for the best possible 
rotamer using the SCRWL library in YASARA version 12.8.6.112 The variant 
structures were subjected to rounds of steepest descent and annealing energy 
minimizations. Subsequently MD simulation was performed for 10 ns 
(nanosecond) for each mutated structure as well as the wild type. The 
simulation trajectory for both wild type and mutant proteins were analyzed with 
respect to each other. 
 
4.4 Results 
 
4.4.1 Characterization of patients 
 
 
Genotype, laboratory parameters, bleeding symptoms and bleeding scores (BS) 
of all five patients are presented in Table 4.1. Mutation analysis revealed 6 
different variants (p.Cys1227Arg, p.Cys2085Tyr, p.Cys2283Arg, p.Cys2327Trp, 
p.Cys2619Tyr, p.Cys2676Phe) all presented in heterozygous state. In four 
patients the mutations were detected as single gene defect associated with type 
2A VWD (patients 1 and 3) and type 1 VWD (patients 4 and 5). Both mutations 
p.Cys2283Arg and p.Cys1227Arg were detected in type 3 VWD (patient 2). All 
mutations, except p.Cys1227Arg were localized in the C-terminal end of VWF 
(domain D4, B, C2 and C2-CK, corresponding to D4, C1, C5 and C6 domains 
up-dated by Zhou et al).19 Bleeding symptoms and BS were recorded in relation 
to the VWD type. 
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# VWD  Type 
Nucleotide 
exchange 
AA 
exchange 
Domain 
original 
designations 
Domain 
updated 
designations  
VWF:Ag  
IU/dL 
VWF:RCo  
IU/dL 
FVIII:C  
IU/dL 
Multimer 
pattern 
Bleeding Score 
(BS) 
Bleeding 
symptoms 
1 2A c.6254G>A p.Cys2085Tyr D4 D4 22 13 42 Abnormal 13 1,2, 3, 5 
2 3 c.6847T>C p.Cys2283Arg D4 C1 3 5 6 No 
multimer 15 
1, 2, 3, 5, 
6, 10 
  c.3679T>C p.Cys1227Arg D3        
3 2A c.6981T>G p.Cys2327Trp B C1 13 7 22 Abnormal 20 1, 2, 3, 4, 6, 8, 9 
4 1 c.7856G>A p.Cys2619r C2 C5 37 43  Normal 6 5, 7 
5 1 c.8027G>T p.Cys2676Phe C2-CK C6 39 30 84 Normal 3 1,7 
 
 
Table 4.1. Mutations and phenotypic characteristics of patients. 
The numbers listed in bleeding symptoms column represent: 1 = Epistaxis, 2 = easy bruising, 3 = bleeding from minor wounds, 4 = 
bleeding from oral cavity, 5 = bleeding after tooth extraction, 6 = postoperative bleeding, 7 = menorrhagia, 8 = postpartum hemorrhage, 9 
= muscle hematomas, 10 = CNS bleeding.  
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4.4.2 Expression of VWF mutations in human cell lines 
 
To characterize the effect of the identified mutations on VWF processing, 
transient transfections were performed and rVWF:Ag levels were measured in 
both the conditioned culture media and cell lysates and expressed as a 
percentage of the corresponding wild-type rVWF levels. Five expression vectors 
corresponding to each mutation were homozygously expressed in HEK293T 
cells.  All mutants demonstrated severely impaired secretion. The detected 
rVWF:Ag  levels in medium were significantly lower compared to the WT, 
ranging from  7% to 23% of rVWF-WT (Figure 4.1, left side). To mimic the 
heterozygous patient state, co-expression of four mutants (p.Cys2085Tyr, 
p.Cys2327Trp, p.Cys2619Tyr, p.Cys2676Phe) together with WT were 
additionally performed. The rVWF:Ag values showed reduction in secretion, in 
the range of 45.7 to 59.5% of WT (Figure 4.1, right side).  
Furthermore, co-expression of variants p.Cys2283Arg and p.Cys1227Arg 
(representing the compound heterozygous state of type 3 VWD patient) resulted 
in strongly reduced secretion of VWF to 19% (Figure 4.1, right side).  
The measurement of intracellular rVWF:Ag of all mutants showed values higher 
than that of the WT, indicating intracellular retention of rVWF-mutants (Figure 
4.1).  
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Figure 4.1. Recombinant VWF levels in medium and lysates.  
Recombinant VWF antigen levels (VWF:Ag) in medium (white bars) and lysate (black 
bars) are expressed as percentage relative to the amount of VWF:Ag in the medium 
and lysate of cells expressing WT-VWF. Each column represents the mean and 
standard deviations of at least three independent experiments in triplicate. Co-
transfections of WT and mutant VWF cDNA were done with a 1:1 ratio. 
 
 
4.4.3 Functional characterization of recombinant VWF mutants  
 
The multimer distribution of the recombinant variants demonstrated a range of 
structural abnormalities (Figure 4.2). Single transfections rVWF-p.Cys2085Tyr, 
p.Cys2283Arg and p.Cys2676Phe exhibited only dimers and tetramers. 
Multimer analysis of secreted rVWF-p.Cys2327Trp revealed a complete lack of 
intermediate and high molecular weight multimers, whereas rVWF-
p.Cys2619Tyr showed loss of most of intermediate multimers and lack of 
HMWM (Figure 4.2 A). Interestingly, variant C2327W additionally showed shift 
in mobility of multimer bands (Figure 4.2 A). 
Figure 4.2B illustrates the multimer patterns for co-expressed mutants and WT 
as well as for co-expression of the two mutants p.Cys2283Arg and 
p.Cys1227Arg, identified in the type 3 VWD patient. The co-expression of WT 
with mutants p.Cys2619Tyr and p.Cys2676Phe led to secretion of the full range 
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of VWF multimers. This profile corresponds to the multimer pattern observed in 
patient with type 1 VWD (Figure 4.2C). The multimer structure of the second 
group of co-expressions of p.Cys2085Tyr/WT, p.Cys2327Trp/WT and 
p.Cys2283Arg/WT showed a reduction of the largest multimers in secreted 
VWF compared with WT which is in correlation with type 2A patients’ 
phenotype. The observed reduction is so intensive in co-expressions of 
p.Cys2085Tyr/WT that even leads to the loss of the largest multimers. The 
p.Cys2283Arg/p.Cys1227Arg co-expression resulted in detection of only a few 
low molecular weight multimers. 
Functional assessment of heterozygously expressed variants are presented as 
ratios of VWF:RCo, GPIb binding and VWF:CB to VWF:Ag of secreted VWF in 
Table 4.2. Since the VWF levels in media of single mutant transfection of 
mutants were too low for reliable quantification, VWF activity assays were only 
performed for co-expressions of mutant/WT. Co-expressions p.Cys2085Tyr/WT, 
p.Cys2283Arg/WT and p.Cys2327Trp/WT with impaired multimer structure 
showed decrease in ratios VWF:RCo, GPIb binding and CB to VWF:Ag 
compared with those of rVWF-WT (p<0.05), while variant p.Cys2619Tyr/WT 
with a normal multimer had normal binding activities as expected. However, 
p.Cys2676Phe/WT revealed reduced VWF activities (p<0.05 vs. wild type) in 
spite of normal multimer.  
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Figure 4.2. VWF multimeric 
analysis of patients and 
secreted rVWF after SDS-
agarose gel electrophoresis. 
Panels A and B illustrate 
multimer analysis of rVWF-
mutants in medium after single 
transfections and cotransfections, 
respectively, compared to rVWF-
WT. Arrows indicate anodic shifts 
of multimeric bands observed for 
rVWF-p.Cys2327Trp. Boxes 
indicate reduction or loss of large 
multimers. Panel C represents 
multimer analysis of patients’ 
plasma. 
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Table 4.2. Functional assays of secreted recombinant VWF proteins. 
Mean and standard deviations of ratios VWF:RCo, GPIb and CB to VWF:Ag of  
three independent co-experiments in triplicate. 
 
4.4.4 Susceptibility of variants to cleavage by ADAMTS13 
 
We investigated whether mutants have altered susceptibility to ADAMTS13 
proteolysis. Proteolytic degradation of rVWF-mutants was compared to that of 
the rVWF-WT. No difference in the sensitivity of the rVWF mutants to cleavage 
by ADAMTS13 has been demonstrated (Figure 4.3). 
 
 
 
 
 
 
 
 
  
VWF:RCo/VWF:Ag 
 
VWF:GPIb/VWF:Ag 
 
VWF:CB/VWF:Ag 
 
WT 0.779 ±  0.205 0.717± 0.108 0.625 ± 0.103 
p.Cys2085Tyr/WT 0.632 ± 0.131 0.538 ± 0.036 0.408 ± 0.139 
p.Cys2283Arg/WT 0.496 ± 0.129 0.581 ± 0.068 0.543 ± 0.131 
p.Cys2327Trp/WT 0.465 ± 0.026 0.591 ± 0.064 0.471 ± 0.017 
p.Cys2619Tyr/WT 0.703 ± 0.133 0.709 ± 0.054 0.526 ± 0.063 
p.Cys2676Phe/WT 0.611± 0.057 0.529 ± 0.035 0.426 ± 0.088 
Figure 4.3. Multimer analysis of heterozygously expressed rVWF after digestion 
with rADAMTS13 in vitro. The secreted rVWF was concentrated and then was 
cleaved by recombinant ADAMTS13. The figure illustrates the multimer pattern of 
digested mutated and rVWF-WT after electrophoresis on 1.6% SDS_agarose gel.  
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4.4.5 Intracellular localization  
 
Intracellular trafficking and the impact of mutations on granule formation were 
analyzed after expression of mutants in HEK293 cells. HEK293 cells form 
pseudo-WPB granules when transfected with rVWF-WT.101, 113 Confocal 
microscopy showed no retention of all mutant rVWF in either the ER or in the 
cis- or trans-Golgi compartments (Figures 4.4 and 4.5). Each of the VWF 
mutants was able to form pseudo-WPB storage granules (Figure 4.6, presented 
as small dots), although those granules had different morphology from normal 
cigar-shaped granules formed by rVWF-WT. The majority of the pseudo-WPB 
granules formed by mutants were relatively shorter. We also investigated the 
impact of VWF variant heterozygosity on storage in pseudo-WPB granules. 
Upon co-transfection with rVWF-WT, the defects in the elongation of the 
pseudo-WPB granules caused by mutations were partially corrected.  
                                                                                                        
 
Figure 4.4 Subcellular localization of 
rVWF-WT and variants in relation to 
endoplasmic reticulum (ER) in 
transfected HEK293 cell lines.  
Fixed cells were stained for VWF (green 
channel, left panel) and for PDI (ER marker, 
red channel, middle panel). Right panel 
illustrates the merge of green and red 
channels.  Scale bars, 10 µl. 
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Figure 4.5. Subcellular localization of rVWF-WT and variants in transfected 
HEK293 cell lines.  
In Panel A, fixed cells were stained for VWF (green channel, left panel) and for 
GM130 (Cis-Golgi  marker, red channel, middle panel). Right panel illustrates the 
merge of green and red channels.   
In Panel B, fixed cells were stained for VWF (green channel, left panel) and for 
TGN46 (Trans-Golgi  marker, red channel, middle panel). Right panel illustrates 
the merge of green and red channels.  Scale bars, 10 µl. 
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Figure 4.6. Intracellular storage of rVWF-WT and mutants in HEK293 cells. 
The pseudo-WPB granules formed after single transfections of HEK293T cells with WT 
and mutated constructs and mock transfected cells. Pseudo-WPB granules are shown 
in green (VWF staining). Pseudo-WPB granules in cells expressing rVWF-WT have 
cigar-shaped appearance, while they are round and shorter in cells expressing rVWF-
mutants. Scale bar = 10µm. 
 
 
4.4.6 Impact of the mutations on VWF structure   
 
Homology modeling 
       
The C1, C5 and C6 domains (according to the Zhou et al) are cysteine rich 
domains characterized by multiple cysteine disulfide bonds.19 The domains 
comprise of short beta strands linked by a combination of beta turns and 
hairpins with the occasional short beta bulge (C6) or alpha helix (C5 & C6) 
(Figure 4.7). Only the C1 domain shows unpaired cysteines (n=4) (Figure 4.7), 
the remaining cysteines form intra-domain/intrachain disulfide bonds.  
 
 
 
Chapter 4. Cysteine missense mutations and VWF biosynthesis 
 
- 69 - 
 
 
 
 
 
 
 
 MD simulation and stability prediction 
 
The simulation of the monomeric C1, C5 and C6 domains showed high RMSD 
(root mean square deviation) which finally stabilized between 2-2.5A°. 
Comparison of trajectory RMSD for the short period of 10 nanoseconds showed 
differences between the mutation and the wild type structures (Table 4.3). 
Trajectory analysis for other components such as accessible surface area and 
the radius of gyration also showed differences between the mutations and the 
wild type (Table 4.3). Folding energy calculations showed a high impact for all 
the mutations except p.Cys2327Trp in C1 domain. The p.Cys2283Arg mutation 
results in the replacement of a buried conserved disulfide bonded cysteine 
residue to a polar, charged and large Arg residue which is partly surface 
exposed (Figure 4.8, Panel A). The p.Cys2327 residue was the only cysteine 
that is observed at the interface of the C-domain dimer models (models not 
shown). The p.Cys2327Trp mutation was also the only cysteine residue 
Figure 4.7. Homology models for C1, C5 and C6 domains. 
Panels A, B and C show ribbon diagrams for the homology models of C1, C5 and C6 
domains. The cysteines (unpaired and bound) are represented in stick forms. The 
accessible surface areas of the unpaired and bound cysteines are represented as 
blue spheres. The arrows in Panel A show the unpaired cysteines in Domain C1. The 
pink boxes show the position of Cys2283 and Cys2327 in C1 domain, Cys2619 in C5 
domain and Cys2676 in C6 domain. 
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mutation amongst the ones we reported which belongs to the unpaired cysteine 
(no intra-domain disulfide bond) category. This cysteine was partly surface 
exposed and also present at the C1-C1 dimer interface (in the dimer model) 
(Figure 4.8, Panel Biii) at the C-terminal end of the domain (which connects to 
the C2 domain). The affected cysteine in the C5 domain p.Cys2619Tyr 
represents the substitution of a conserved disulfide bonded cysteine with an 
aromatic tyrosine side chain. The disulfide bond for the p.Cys2619 residue 
belongs to the RHStaple category of disulfide bonds (Table 4.4). The mutation 
p.Cys2676Phe in the C6 domain results in the replacement of a highly 
conserved disulfide bonded cysteine with a large aromatic and highly 
hydophobic Phe side chain. During simulation the mutated Phe side chain is 
accommodated within the domain (Figure 4.8, Panel D). 
 
 
 
Table 4.3. Structural changes observed during MD.  
The structural characteristics are represented side by side for wild type/mutant residue.  
B: Bonds broken/added post mutation, A.S.A: Average surface accessible area for the 
simulation trajectory (in Angstrom units), R.O.G: Radius of gyration for the simulation 
trajectory (in Angstrom units), R.M.S.D: Average R.M.S.D for the simulation trajectory 
(in Angstrom units), Charge: Charge added or removed on mutation, ∆∆G: Average 
change in folding energy for mutation calculated with FOLDX [The stability of the 
mutated structure was estimated as the difference between the free energy (calculated 
from folding/unfolding algorithms) of the wild type protein and that of the mutant protein 
represented as ∆∆G values (stability/free energy changes);reported in kJ/mol; higher 
values indicate an unstable protein]. The numbering of cysteines mentioned in the 
second column is according to their linear appearance in the modelled domain 
structures. 
Residue B (Disulphide Bond) A.S.A R.O.G R.M.S.D Charge ∆∆G 
p.Cys2283Arg 4CYS-30CYS 2.01/47.02 17.42/20.03 2.24/4.67 + +12.20 
p.Cys2327Trp - 47.25/83.91 17.42/18.01 2.24/2.32 0 +0.17 
p.Cys2619Tyr 26CYS-42CYS 44.40/139.98 16.32/18.15 2.13/3.24 0 +7.65 
p.Cys2676Phe 3CYS-30CYS 1.07/3.79 17.58/16.46 2.07/3.52 0 +8.51 
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Figure 4.8. Close-up view of mutated and wild type residue after MD simulation. 
The representations are in surface diagrams with the backbone depicted in ribbon 
form. The affected residues are illustrated as blue stick representations. The surfaces 
of the model and affected residue are depicted in gray and magenta surface 
representations. The accessible surface area for the residues is highlighted by dotted 
rectangles and squares. 
Panel A shows the wild type p.Cys2283 (i) and mutant p.Cys2283Arg (ii) after 10 
nanoseconds of MD simulation. The cleavage of a disulfide bond and a distinct gain in 
accessible surface area is noticeable for the mutant residue. Panel B shows the wild 
type p.Cys2327 (i), mutant p.Cys2327Trp (ii) and the C1 dimer interface (Iii) after 10 
nanoseconds of MD simulation. The Figure (iii) emphasizes the closeness of this locus 
to the hypothetical interface area (the neighboring surfaces of the individual monomers 
are colored in separate shades of gray and the interface is marked by dotted lines). 
The mutant residue shows a gain in accessible surface area with most of the Trp 
aromatic side chain exposed to the surface. Panel C shows the wild type p.Cys2619 (i) 
and mutant p.Cys2619Tyr (ii) in C2 domain after 10 ns of MD simulation. The mutant 
residue shows the breakage of disulfide bond and a large aromatic Tyr side chain 
almost completely surface exposed. Panel D shows the wild type p.Cys2676 in C6 
domain (i), mutant p.Cys2676Phe (ii) and contact interference (iii) after 10 
nanoseconds of MD simulation.  The Fig (iii) shows mutated Phe residue 
accommodated into the protein scaffold resulting in contact problems with the 
neighbouring residues which are shown as colored lines.  
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Domain Disulfide bond Chi1 Chi2 Chi3 Chi2´ Chi1´ Type of Disulfide bond 
C1 4 CYS-30CYS -165.6 79.7 77.3 130.3 -143.8 -RHSpiral 
C5 26CYS-42CYS -43.5 -101.8 91.3 -86.9 -50.5 -RHStaple 
C6 3CYS-30CYS -66.8 -169.6 -101.3 169.0 59.5 +/-LHHook 
 
Table 4.4. Cysteine Disulfide bonds.  
The table lists the torsional angles for disulfide bonds on which mutations have been 
identified and the classification of these disulfide bonds based on the nature of (+or-) 
the torsional angles. Classification based on the sign of disulfide bonds (+: grey,-: 
blank) is annotated from previous literature as well as disulfide bond analysis file 
(disulfide_analysis_06_Aug_2012.zip) accessed on 07/10/2012 
(http://www.med.unsw.edu.au/CRCWeb.nsf/page/Disulfide+Bond+Analysis). 
 
 
4.5 Discussion 
 
This study presents the functional characterization of five cysteine mutations 
occurring in the C-terminal domains of VWF. The results showed that these 
mutations had disruptive impacts on multimerization, storage and consequently 
secretion of VWF. The last two characteristics were partly corrected when the 
mutations were co-expressed with rVWF-WT. While the multimer structures of 
p.Cys2676Phe and p.Cys2619Tyr were completely corrected by co-expression 
with rVWF-WT, co-expressions of rVWF-WT and p.Cys2085Tyr, p.Cys2327Trp 
and p.Cys2283Arg showed loss or reduction of large multimers indicating a 
dominant negative effect of these mutations on multimerization. In agreement 
with our finding, previous studies have reported impaired multimerization and 
intracellular retention of VWF for some homozygously expressed cysteine 
missense mutations at the C-terminal of VWF.86, 114, 115 Nevertheless, this study 
demonstrates for the first time defect in multimer assembly by heterozygous 
mutations occurring in the D4 and B domains, and presents a new pathologic 
mechanism for dominant type 2A VWD. 
 All mutants exhibited apparent intracellular retention. However, when the total 
produced amount of rVWF (sum of VWF:Ag in medium and lysate) was 
calculated, all mutant rVWF constructs (except p.Cys2327Trp) demonstrated 
statistically significant  reduced expression of rVWF compared to rVWF-WT 
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(p<0.05). These data suggest that the investigated mutations might additionally 
lead to increased intracellular degradation or decreased synthesis. The confocal 
microscopy results excluded retention of mutant rVWFs in the ER and cis- 
and/or trans-Golgi compartments. Punctuate granular pattern observed in 
immunofluorescent staining showed that the mutations interfere with the normal 
elongation of pseudo-WPBs. Previous investigations reported impaired 
formation of normal elongated pseudo-WPB granules for in vitro expression of 
variants located in propeptide, D3 and C-terminal VWF domains. 106, 115, 116 
Co-expressions of WT and either p.Cys2085Tyr, p.Cys2327Trp, p.Cys2619Tyr 
or p.Cys2676Phe mutans clearly reproduced the phenotype observed in 
heterozygous patients. Co-expression of p.Cys2283Arg and p.Cys1227Arg 
variants caused strong reduction in secretion of rVWF, suggesting that these 
mutations are causative for low VWF antigen in patient’s plasma. It is already 
known that p.Cys1227 in the D3 domain participates in an intersubunit disulfide 
bond, critical for multimerization.117 Our in vitro experiments clearly 
demonstrated that the p.Cys2283Arg variant also leads to defect in 
multimeristion assembly in both homozygous and heterozygous states. 
However, the VWF antigen levels and multimer analysis of the co-expressed 
mutants and patient’s plasma showed slight discrepancies. The presence of a 
few low molecular weight VWF multimers in culture medium was in contrast to 
the existence only of dimers in patient’s plasma. This might be explained by 
instability of the low molecular weight VWF multimers composed of mutant VWF 
monomers, and enhanced clearance of them in plasma.  
Both patients with type 2A showed a smeary multimer pattern without 
distinguishable triplet structures indicating altered susceptibility to VWF 
proteolysis by ADAMTS13. Since efficiency of in vitro proteolysis of 
recombinant p.Cys2085Tyr/WT and p.Cys2327Trp/WT by rADAMTS13 was not 
changed compared with rVWF-WT, the altered proteolysis of mutated VWF in 
plasma is likely not an intrinsic property of the mutations but rather the result of 
strong reduction of VWF:Ag level in plasma or unequal experimental and 
circulation conditions.  
Molecular modeling of the cysteine disulfide bonds on the C1, C5 and C6 
domains (update domain designations) suggests a number of hypotheses 
consistent with our experimental results. Our homology models for the C 
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domains revealed that the cysteine residues p.Cys2283, p.Cys2619 and 
p.Cys2676 are involved in intra-chain/intra-domain disulfide bonds (Figure 4.7) 
in C1, C5 and C6, respectively, consistent with the predicted disulfide 
assignment suggested by Zhou et al. 2012.19 The anomalous introduction of a 
surface charge with the p.Cys2283Arg substitution might influence interaction 
on the surface of the domain and the large Arg side chain might result in intra-
domain instability.  The –RH Staple configuration shown by the disulfide bonds 
involving p.Cys2619 residue is typical of disulfide bonds categorized as 
“allosteric” disulfide bonds responsible for regulation of protein functions 
depending on whether they break or form.118,119  Therefore, this bond is critical 
to the overall stability of the domain since the mutation p.Cys2619Tyr in spite of 
breaking a disulfide bond doesn’t show a remarkable change in modeled 
surface exposure (accessible surface area and charge) during simulation (Table 
4.4; Figure 4.8, Panel C).  Accommodating the large aromatic Phe side chain in 
the p.Cys2676Phe mutation in the C6 domain might result in intra-domain steric 
clashes which could damage the overall protein scaffold, and possibly cause 
decreased protein stability (Figure 4.8, Panel Diii). Therefore, the mutations 
p.Cys2283Arg, p.Cys2619Tyr and p.Cys2676Phe all may result in unstable 
domains. This is reflected by changes in the trajectory RMSDs, radius of 
gyrations (during simulation) as well as high folding energy change values for all 
these mutations. The total reduced expression VWF levels in our study also 
indicated protein instability for all these mutations which is in agreement with 
the in sillico data. Our C1 homology model and previous reports suggest that 
p.Cys2327 might be one of the unpaired cysteines participating in inter-domain 
disulfide bond with the neighbouring p.Cys2632 from the C2 domain.19 The 
p.Cys2327Trp is also distinguished from the other mutants in our expression 
analysis by an electrophoretic mobility shift for the multimer bands confirming a 
major conformational change in the protein. This raises the possibility that the 
mutation of this cysteine to the aromatic Trp residue might create a steric 
interference at the point of contact for C2 domain as well as C1 domain from the 
opposite monomer resulting in a conformationally altered protein. Interestingly, 
this mutation unlike the other C-domain mutations, is not predicted to result in a 
large folding energy change suggesting that the variant may not affect protein 
stability in spite of the conformational change. This correlates with our in vitro 
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expression results where total expression level was similar to that of the wild 
type VWF. Interestingly, Tjernberg et al have reported mobility shift in multimer 
for substitutions at p.Cys2362 in the C2 domain which is most likely the 
disulfide-bond partner of p.Cys2327 in C1 domain .120 Although we did not 
perform any structural modeling for the D4 domain, it was predicted that 
p.Cys2085 residue in D4 domain participate in intrachain disulfide bond.19 The 
introduction of large Arg side chain will disrupt the disulfide bond, and might 
cause domain instability. 
In summary, the current structural analysis showed that mutations eliminating 
these cysteine residues could induce misfolding of the respective domains. We 
speculate that such domain misfoldings might influence dimeric bouquet 
formation and consequently helical assembly of tubules and storage. Therefore, 
VWF secretion can be defected since tubular packing of VWF is prerequisite for 
physiological VWF unfurling upon exocytosis.26, 30, 31 Moreover, recent findings 
stated that dimeric bouquet formation facilitates N-terminal disulphide linkage 
between VWF dimers which is colinear with assembly in tubules.31, 32 
Accordingly, we assume that defects in multimerization might be attributed to 
disruption in zipping up of misfolded C domains into dimeric bouquet structures.  
In conclusion, our results indicates that the above described cysteine residues 
have a crucial role in accurate folding of D4 and C1, C5 and C6 domains 
(corresponding to original D4, B and C domains) required for proper 
arrangement of VWF dimer bouquets and their incorporation into growing 
tubules in nascent WPBs. This study demonstrates that these mutations disrupt 
storage, and secretion of VWF through a common pathological mechanism, 
although their eventual outcome on multimerization might differ because of sub-
molecular differences in structural alteratnations. 
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